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 Summary 
 
The design of liposomal carriers for gene or drug delivery is an active field in current 
biomedical research. An important issue is the targeting of the carriers to specific cell types 
for which the therapeutical approach is intended.  
The combination of liposomes and imaging probes such as Quantum Dots (QDs) in a 
single nanoparticle offers an excellent tool for increasing the understanding of the 
mechanisms of liposome uptake thereby increasing the efficiency of gene or drug delivery. 
In the research developed in this thesis, biotinylated lipid particles (BLP) were loaded with 
plasmid DNA and labeled on the surface with QDs functionalized with the ligand EGF 
(Epidermal Growth Factor). In a second and novel approach, BLP were loaded with a red 
emitting QD655 and surface coated with a green emitting QD525 tagged with the EGF ligand. 
This latter approach was intended to monitor the specificity of BLP binding and uptake in live 
cells by fluorescence confocal microscopy. Both types of BLP were targeted to A431 cells, a 
cancer cell line that overexpresses the EGF receptor (EGFR). Furthermore, BLP formulations 
differing in the content of the protective polymer PEG (polyethylene glycol) were tested in 
order to optimize the intracellular delivery of plasmid DNA or QDs. 
The colocalization of green emitting QD525 and red emitting QD655, allowed the immediate 
discrimination of the targeted BLP from the untargeted counterparts, as well as the presence 
of free EGF-QD525 complexes during live cell imaging. EGFR-targeted BLP showed increased 
binding and accelerated uptake as compared to EGF-free BLP. Cellular binding of targeted 
BLP was further associated with the perinuclear localization of QDs in clusters which persisted 
over days, indicating the difficulty in releasing the encapsulated nanoparticles from endo-
lysosomal vesicles. On the other hand, targeted BLP with encapsulated plasmid carrying the 
reporter gene for the Green Fluorescent Protein (GFP) showed enhanced transfection of 
A431 cells compared to that exhibited by non-targeted particles for all lipid formulations 
tested, indicating the occurrence of plasmid release in the cytoplasm. No targeting effect, 
however, was evident in cells devoid of EGF receptor or in the receptor occupied by 
competing free ligand, indicating that enhanced EGFR-targeted delivery is primarily 
mediated via a ligand/receptor interaction. 
From a therapeutic point of view, the specificity displayed by the BLP labeled with two 
colors of QDs and targeted to tumor cells overexpressing the EGF receptor may provide a 
platform for testing the specific delivery of tumorigenic drugs. This approach was also 
intended to elucidate the fate of lipid particles in real time, taking advantages of the 
photostability and bright fluorescence of QDs.  
The designed BLP will provide refined information about the still poorly understood 
trafficking processes and the subcellular barriers to gene or drug delivery via liposomal 
carriers. 
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Abbreviations  
AFM Atomic Force Microscopy 
a.u. arbitrary units 
BLP Biotinylated Lipid Particles 
bp base pair 
BP Band pass filter (optics) 
BSA Bovine serum albumin 
CCD Charged-coupled device 
CHO Chinese hamster ovary cell line 
CLSM Confocal Laser Scanning Microscopy 
cmc critical micellar concentration 
DIC Differential interference contrast  
DLS Dynamic Light Scattering 
DMEM Dulbecco modified Eagle medium 
DNA Deoxyribonucleic acid 
DOPE Dioleoyl-L-a-phosphatidylethanolamine 
DOTAP 1,2-Dioleoyloxy-3-(trimethylammonio)-propane 
DSPE Distearoyl-L-a-phosphatidylethanolamine 
EDTA Ethylenediamine tetraacetic acid 
EGF Epidermal growth factor  
EGFR Epidermal growth factor receptor 
ex./em. excitation/emission wavelengths 
FCS Fetal calf serum 
g gravitational field centrifugation unit 
GFP Green fluorescent protein 
HBS HEPES buffered saline 
HEPES N-(2-hydroxyethyl)piperazine-N´-(2-ethanesulfonic acid) 
kDa kilodalton 
LB Luria Bertani growth medium 
LP Long pass filter (optics) 
mM, μM, nM millimolar, micromolar, nanomolar 
min, h minute, hour 
MWCO Molecular Weight Cut-off 
NA Numerical aperture 
OGP Octylglucopyranoside 
PBS Phosphate buffered saline 
pdi Polydispersity index 
PEG Polyethyleneglycol 
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PEG-Cer-C20 PEG-Ceramide bioconjugate with an arachidoyl acyl group 
PEG-Cer-C8 PEG-Ceramide bioconjugate with an octanoyl acyl group 
PEG-DSGS PEG-[succinoyl]-1,2-distearoyl-sn-glycerol 
pH Negative decadic logarithm of the hydrogen ion (H+) 
concentration 
PNA Peptide nucleic acid 
QD Quantum dot 
RT Room temperature 
SPLP Stabilized Plasmid Lipid Particles 
StAv Streptavidin 
t time 
TEM Transmission Electron Microscopy 
UV Ultraviolet 
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1.1. Molecular therapy 
The genomic information obtained through the Human Genome Project has accelerated 
enormously the analysis of the functions of various disease relevant genes as well as the 
design of therapeutic molecules and delivery systems (Hicks, 2003; Austin, 2004). 
Biomolecules, such as sense and antisense oligonucleotides, small interference RNAs and 
peptides, as well as entire genes (cDNA) and proteins are essential tools in the development 
of molecular therapies (Shi and Hoekstra, 2004; Wagner, 2007). However, the potential of 
such information-rich macromolecules for therapeutic use has been limited by the difficulties 
in delivering them specifically to target tissues in vivo and in discriminating between disease-
affected and normal cells.   
A variety of viral and non-viral vehicles have been conceived to effect the encapsulation, 
in vivo cell targeting and intracellular delivery of therapeutic macromolecules (Maurer et al., 
1999; Gupta et al., 2005; Torchilin, 2006). However, the hostile extracellular environment 
constitutes a primary challenge in the systemic delivery of gene or drug carriers to 
intracellular targets. This presents a number of barriers, such as extreme pH, proteases and 
nucleases and the immune defence and scavenger systems (Figure 1.1). Once the carrier 
reaches the target tissue, the efficient cell binding, uptake and delivery of the cargo into 
and within subcellular compartments is critical for gaining the desired therapeutic effect. At 
this stage, the cell membrane is the main physical barrier due to the poor permeability of the 
lipid bilayer, where the diffusion rate is highly dependent on the size and hydrophobicity of 
the molecular carrier. Therefore, the rational design of intracellular gene/drug delivery 
vehicles requires a better understanding of the cell membrane barrier (Belting et al., 2005).  
1.1.1. Gene delivery 
The realization that nucleic acids could be used as therapeutic agents to alter the 
expression and function of proteins in the body has given an immense boost to transfection 
biology. Gene therapy is a part of the growing field of molecular medicine gaining 
significance in the treatment of human diseases. By delivering genes into cells to regulate or 
supplement defective genetic loci, the morbidity of inherited and acquired diseases can be 
alleviated (Civin, 2000; Edelstein et al., 2007). 
In most procedures to date, nucleic acids have been encapsulated in vehicles that both 
protect the therapeutic gene and allow its extracellular and intracellular trafficking. Most 
DNA delivery systems operate at one of three general levels: DNA condensation and 
complexation, endocytosis, and nuclear membrane translocation (Luo and Saltzman, 2000). 
Negatively charged DNA molecules are usually condensed and/or complexed with cationic 
lipids or polymers before the delivery into cells. These complexes are taken up by cells usually 
1. Introduction and aims of the thesis 
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through an endocytic mechanism, which determines subsequent DNA release, trafficking, 
lifetime and function in the cell (Guy et al., 1995). 
 
Figure 1.1: Illustration of barriers for systemic gene delivery. DNA-containing nanoparticles are 
injected intravenously into human body. Serum proteins may bind to the particles, crosslink them and 
increase the particle size. This can result in rapid particle elimination (Insert 1). The Kupffer cells (RES) 
may take up particles, leading to rapid nanoparticles elimination from circulation and decrease their 
access to the hepatocytes (Insert 2). Circulating nanoparticles may extravasate in tumor tissue through 
the leaky tumor vessels (Insert 3). Particles then need to pass through the crowded extracellular matrix 
to contact the cell surface (Insert 4). When the particles are internalized into cells, DNA must escape 
from the endosome and find its way into the nucleus (Insert 5). Adapted from (Weijun Li, 2007). 
1.2. Viral and non-viral gene delivery systems  
1.2.1. Viral vectors 
Viruses in nature have evolved an exceptional ability for delivering their genome into cells, 
responding to changes in the cellular environment and gaining access to their desired 
intracellular compartments (Vives et al., 2006). 
A number of different viruses, such as retrovirus, adenovirus, adeno-associated virus and 
herpes virus have been widely studied in gene transfer systems attracting the most attention 
in the field of transduction (Zhang and Godbey, 2006). Retroviral vectors were the first viral 
1. Introduction and aims of the thesis 
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vectors to enter clinical trials and continue to be attractive candidates for applications 
where integration of the transgene is required (Cornetta K, 2008).  
Virus-based vectors are modified by removing certain viral genes associated with 
pathogenic function. Other approaches mimic the viral machinery required for cell binding 
and internalization by coupling modified proteins from the viral capside to the surface of 
therapeutic carriers (Boeckle and Wagner, 2006). In fact, more than 70% of recent clinical 
protocols involving gene therapy use recombinant virus-based vectors for DNA delivery 
(Cornetta K, 2008). However, these delivery systems are restricted by their limited DNA 
carrying capacity, toxicity and potential oncogenicity, factors that hamper their routine use 
in basic research laboratories (Anderson, 1998; Boeckle and Wagner, 2006).  
1.2.2. Non-viral vectors 
Synthetic non-viral vectors have many potential advantages over viral ones, including a 
size-independent delivery of nucleic acids ranging from oligonucleotides to artificial 
chromosomes, significantly reduced toxicity and immunogenicity, and lower potential for 
oncogenicity (Luo and Saltzman, 2000). Additionally, they involve less demanding quality 
controls, and less complex pharmaceutical and regulatory requirements. However, these 
reagents still demonstrate reduced transfection efficiencies and transient levels of gene 
expression compared to the viral vehicles (Lechardeur et al., 2005; Mehier-Humbert and Guy, 
2005).  
Non-viral approaches include physical methods for introducing naked DNA directly into 
the cell, such as particle bombardement, microinjection and electroporation (Chou et al., 
2004; Mehier-Humbert and Guy, 2005). The drawbacks of these systems are the limited 
number of cells that can be treated and the possible physical damage to the cell 
membrane.  
Widespread approaches involve chemical methods to enable the cellular uptake of 
insoluble or highly charged macromolecules. Chemical carriers are based on peptides, lipids 
and phospholipids mixtures as well as polymers (Kramer et al., 2004; Kneuer et al., 2006) which 
form complexes with the cargo molecules such as drugs or DNA. In these delivery systems, 
the cargo does not get into contact with the cell surface molecules, so that unspecific 
interactions are omitted. Chemical carriers enhance the uptake of macromolecules by 
facilitating either direct cell translocation (Merkleb, 2004) or endocytosis (Hoekstra et al., 
2007). Lipid or polymer-based delivery systems have now become the major tools to 
introduce not only nucleic acids but also proteins, peptides and nanoparticles into cultured 
cells. 
The scope of non-viral delivery systems have been expanded by the incorporation of 
environment-sensitive polymers, carefully designed to take advantage of intracellular 
changes in pH and temperature in order to achieve a controlled release of the therapeutic 
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molecule (Heath et al., 2007). Furthermore, to achieve active transport of DNA through the 
nuclear pore complex, nuclear localizing signal (NLS) peptides have been widely used 
(Branden et al., 2001; Simonson et al., 2005). In most cases, NLS is conjugated with a gene 
carrier such as polyethylenimine (PEI) or with DNA directly. 
1.3. Lipid-based delivery systems 
The most studied and widespread non-viral approaches for deliverying DNA have been 
those based on lipids. A breakthrough was achieved when Felgner reported for the first time 
that complexes of plasmid DNA and the cationic lipid dioleyl-trimethylammmonium chloride 
(DOTMA) at a 1:1 molar ratio with dioleoylphosphatidylethanolamine (DOPE), were avidly 
internalized by cells and caused profound expression of the plasmid (Felgner et al., 1987). 
Cationic lipid/nucleic acid complexes or lipoplexes have been the subject of intensive 
investigation in recent years. The main focus has been the characterization of the molecular 
mechanisms of lipid-vector and cell membrane interaction, essential for overcoming 
intracellular barriers (Felgner and Ringold, 1989; Simoes et al., 2005; Wasungu and Hoekstra, 
2006; Hoekstra et al., 2007). 
Originally developed for the transfection of DNA, lipid vectors have become the major 
tools for introducing not only a variety of nucleic acids but also proteins, peptides and 
nanoparticles into cells in vitro and in vivo (Maurer et al., 1999; Audouy and Hoekstra, 2001; 
Torchilin et al., 2003). 
The other major field of lipid-based delivery systems arose from the observation that 
phospholipids in aqueous systems can form closed bilayered structures, known as liposomes 
(Lasic and Papahadjopoulos, 1995). These particles comprising an outer lipid layer 
membrane surrounding and internal aqueous space can be loaded with therapeutic 
biomolecules (Mayer et al., 1989). Liposomes can encapsulate and facilitate the delivery of 
plasmid DNA containing therapeutic genes with sizes of several kilobases (Fenske and Cullis, 
2005).  
Liposomes represent a flexible platform for encapsulation since they can range from 
multilamellar vesicles (MLVs) with diameters of several microns to small unilamellar vesicles 
(SUV) of about 20 nm. For biomedical applications, particles with the greatest utility have 
diameters of ~100 nm, large enough to carry a significant payload but small enough to ‘slip’ 
between leaky endothelial junctions escaping the immune system surveillance (Szoka and 
Papahadjopoulos, 1980).  
1.3.1. Components of lipid-based nanoparticles 
Usually, the nanosized lipid particles are constructed from a combination of synthetic and 
natural lipids, lipopolymers and pH or reduction-sensitive components. For most of these lipid-
based particles, cationic lipids are the key elements used to package the DNA (Zuidam and 
1. Introduction and aims of the thesis 
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Barenholz, 1999). An added advantage of the cationic lipids is that they can bind to 
negatively charged mammalian cell membranes inducing the uptake of the associated 
nucleic acid into cells. Neutral lipids such as the fusogenic lipid 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) and cholesterol are usually used as helper lipids which may 
increase transfection activity of the DNA-containing lipid-based carrier (Hafez and Cullis, 
2001). For example, DOPE has a phosphoethanolamine head group whose size is smaller 
than its hydrophobic diacyl chain facilitating membrane fusion and disruption, and 
consequently the DNA release (Zuhorn et al., 2005). 
1.3.2. Sterically Stabilized Liposomes 
The fast and efficient clearance of conventional liposomes from the circulation by 
macrophages has seriously compromised their application for the treatment of a wide range 
of diseases involving other organs. The incorporation of the hydrophilic and biocompatible 
polymer polyethylene glycol (PEG) improved the lifespan of liposomes in the bloodstream 
and reduced cell toxicity, leading to a renewed interest in liposomal carriers during the 90’ 
(Lasic et al., 1991). PEG has been covalently linked to natural and synthetic lipids, which were 
subsequently incorporated into liposome formulations (Bhadra et al., 2002). The PEG polymer 
acts like a shield protecting the encapsulated therapeutic agent from enzymatic 
degradation, rapid renal clearance and interactions with cell surface proteins, thereby 
minimizing adverse immunological effects (Woodle and Lasic, 1992). Figure 1.2 schematically 
depicts a conventional liposome and the advanced sterically stabilized liposome surface- 
coated with PEG.  
 
Figure 1.2: Schematic representation of a conventional liposome and a sterically stabilized PEG-
liposome. Adapted from Encyclopedia Britannica (online). 
 
‘Pegylation’ is now established as the method of choice for improving the 
pharmacokinetics and pharmacodynamics of liposomes. However, once the liposomal 
carrier reaches the cell surface, pegylation may interfere for instance with the endocytic 
mechanism of uptake by either lowering the binding affinity to cell receptors or by 
preventing the intermembrane contact between liposomal surface and endosomal 
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membranes, required to release the cargo in the cytoplasm (Shi et al., 2002; Song et al., 
2002). Therefore, PEG-lipids included in liposomal formulations should dissociate from the 
complex, once the liposome is in close contact with endosomes upon internalization. This has 
been accomplished by incorporating a short acyl chain lipid-PEG to the liposome 
formulation with the ability to promote within minutes the lipid transfer from the liposome 
bilayer (Harvie et al., 2000). Alternatively, by adding a cleavable, pH-sensitive PEG analogue 
in which the polymer moiety is cleaved off upon exposure to the acidic environment of 
certain endosomal compartments (Kirpotin et al., 1996; Guo and Szoka, 2001; Shi et al., 2002; 
Choi et al., 2003; Guo et al., 2003). 
Current development is focused on combining long-term circulating (Lasic et al., 1999) 
and targeted liposomes (Sofou and Sgouros, 2008). The later feature, achieved by 
incorporating a suitable ligand or antibody to the liposome surface, is essential for improving 
the specificity for target cells. 
1.3.3. Stabilized Plasmid-Lipid Particles (SPLP) 
Employing a detergent dialysis technique (Hofland et al., 1996), plasmid DNA has been 
encapsulated with a 50-70% efficiency in small particles (~70 nm) stabilized by PEG-Ceramide 
lipids (Wheeler et al., 1999). These nanocarriers, known as a Stabilized Plasmid Lipid Particles 
(SPLP), have been further improved by several groups by adding pH-sensitive lipids and 
ceramides with shorter carbon chains to confer endosamal escape capabilities (Mok et al., 
1999; Wheeler et al., 1999; Fenske et al., 2002; Li et al., 2005).  
The first generation SPLP developed by Wheeler et al. contained a high percentage of 
the helper lipid DOPE (84 mol%), low levels of cationic lipid dioleyl-dimethylammonium 
chloride DODAC (6 mol%) and quite high levels (10 mol%) of PEG-Ceramide with an 
arachidoyl acyl group (PEG-Cer-C20). The release half-life (t1/2) of PEG-Cer-C20 from SPLP 
was 13 days, becoming an intractable steric barrier to transfection. The length of the 
ceramide lipid anchor determined the time that the PEG conjugate remained associated 
with the bilayer. When PEG-Cer-C20 was replaced by PEG-Cer-C8  with an octanoyl acyl 
group, the t1/2 was reduced to 1.2 min, considerably increasing the transfection of cells in 
vitro (Mok et al., 1999). This first generation of SPLP was improved by Szoka and coworkers 
(Choi et al., 2003; Li et al., 2005) by adding a pH sensitive PEG-lipid to trigger plasmid release 
in the acidic endosomal environment. The key design feature of such PEG-lipids is that the pH 
triggerable PEG-linker should be completely stable at pH 7 and sufficiently destabilized at pH 
5.5, as to irreversibly dissociate within at least 1 hour, essential requirement to ensure 
quantitative release of nucleic acid from the lipid particle. 
As mentioned above, entrapment of plasmid DNA in SPLP was accomplished by a 
detergent dialysis procedure (Hofland et al., 1996) by which reconstituted liposomes consist 
of unilamellar vesicles regardless of the rate of detergent removal (Figure 1.3). As the 
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detergent is being removed, a series of micelle-micelle interactions are initiated to minimize 
the unfavourable energy resulting from the exposure of lipids to the aqueous medium (Figure 
1.3 I). At a critical micelle size, the amplitude of the bending is sufficient to cause bilayer 
closure (Figure 1.3 II) and plasmid encapsulation (Figure 1.3 III). One of the most important 
aspects of SPLP is their great structural integrity with negligible variation in size or DNA 
encapsulation after 5 months at 4 °C. 
 
 
Figure 1.3: Schematic representation of SPLP formation during detergent dialysis. Detergent removal 
from lipid-detergent micelles causes the transformation of small micelles into larger ones (I), which bend 
upon further detergent removal to form curved mixed micelles and trapp the plasmid DNA (II). The 
bilayer becomes continuous forming the stable plasmid-lipid particles (III). Adapted from (Jean-Louis 
Rigaud, 1998). 
 
SPLP have been designed for long-term circulation in vivo but given the severity of the 
extracellular environment, only a modest detectable transfection in animals post i.v.-
administration has been reported (Monck et al., 2000). SPLP systems are now under 
evaluation in Phase I clinical trials (Protiva, unpublished data). 
1.4.  Cell mechanisms of liposome uptake 
The cellular uptake of liposomes is generally believed to be mediated by adsorption of 
liposomes onto the cell surface and subsequent endocytosis. As previously described, the 
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rate limiting steps in this process are the efficiency of cell surface association, internalization, 
release of loaded drug/genes from intracellular compartments such as endosomes, transfer 
to the cytosol and eventually, translocation into the nucleus. 
Liposomal carriers can adsorb specifically and non-specifically to the cell surface (Figure 
1.4 a, b), in some cases promoting a direct delivery of the therapeutic agent into the 
cytoplasm (Figure 1.4 c, d). Additionally, in order to increase the initial cell binding, delivery 
carriers have been modified with cationic moieties to increase the electrostatic interaction 
of the vehicle with the negatively charged cell membrane (Figure 1.4 e, c). Constructs that 
are more sophisticated involve the covalent binding of a ligand or antibody to the liposome 
carrier to promote the specific receptor-mediated or antigen-mediated endocytosis, 
respectively (Figure 1.4 a). If uptake occurs via endocytosis (Figure 1.4 f), receptor or non-
receptor mediated, the liposomes end up in endosomal compartments.  
In the case of receptor-mediated endocytosis, internalized vesicles and their content are 
sorted mainly to the lysosomal compartment for degradation of the ligands and the loaded 
cargo (Figure 1.4 f, g). This also accomplishes the downregulation of activated receptors 
(Shepherd, 1989). However, the majority of targeted deliveries aim to avoid lysosomal 
trafficking in an effort to protect the drug molecule or biomolecules from enzymatic 
degradation. 
Lysosomes, as well as the endoplasmatic reticulum (ER), Golgi apparatus, and endosomes 
are, to a variable degree topologically continuous with the exterior of the cell, i.e. the exit of 
macromolecules from any of these compartments requires passage through a lipid bilayer.  
In general, the endocytosis mechanisms can be divided into clathrin-dependent and 
clathrin-independent. There is a close relation between particle size and the preferred 
internalization pathway, although the correlation is not absolute. Rejman et al. proposed that 
particles <200 nm are taken up via the clathrin-dependent mechanism whereas larger 
particles (250-500 nm) enter the cell through caveolin 1-rich vesicles (Rejman et al., 2004). This 
correlation, between particle size and uptake pathway, is indeed plausible since some of 
these pathways are constrained to the size of their vesicles – e. g. clathrin-coated and 
caveolae-derived vesicles (Pelkmans et al., 2004).  
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Drug or 
DNA 
 
Figure 1.4: Liposome uptake and intracellular fate: DNA or drug loaded liposomes can specifically 
(a) or nonspecifically (b) adsorb onto the cell surface. Liposomes can also fuse with the cell membrane 
(c), and release their content into the cytoplasm, or can be destabilized by certain cell membrane 
components when adsorbed on the surface (d) so that the released drug can enter the cell via 
micropinocytosis. Liposomes can undergo the direct transfer or protein-mediated exchange of lipid 
components with the cell membrane (e) or be subjected to a specific or nonspecific endocytosis (f). In 
the case of endocytosis, liposomes can be directed into lysosomes (g) or, in route to the lysosome, they 
can provoke endosome destabilization (h), which results in the liberation of the therapeutic agent into 
the cell cytoplasm (Adapted from (Torchilin, 2005). 
 
Clathrin-mediated endocytosis serves as the main mechanism of internalization for 
macromolecules and plasma membrane constituents for most cell types and it is the most 
investigated vesicular pathway for targeted drug delivery. This is initiated by the formation of 
clathrin-coated pits, which are subsequently pinched off and internalized. The clathrin coat is 
removed and multiple vesicles fuse originating the early and late endosomes that ultimately 
fuse with lysosomes (Mousavi et al., 2004). 
1.4.1. Receptor-mediated endocytosis as a route for targeted liposomal delivery 
Targeting is usually achieved by conjugating a high affinity ligand to the carrier that 
provides preferential accumulation of the latter for instance, in a tumor-bearing organ, in the 
tumor itself, in individual cancer cells or intracellular organelles. In most cases the targeting 
moieties (ligands or antibodies) are directed toward specific receptors or antigens exposed 
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on the plasma membrane (Kato and Sugiyama, 1997). The overexpression of receptors or 
antigens in many human cancers lends itself to efficient drug uptake via receptor-mediated 
endocytosis. Folate and Transferrin are widely applied ligands for liposome targeting 
because their cognate receptors are frequently overexpressed in a range of tumour cells  
(Kakudo et al., 2004; Hilgenbrink and Low, 2005). Liposomes tagged with various monoclonal 
antibodies have been delivered to many targets (Park et al., 2001).  
The performance of non-viral vector could be certainly optimized by targeting them into 
distinct cellular internalization pathways, considering that not every pathway may be equally 
effective in releasing a therapeutic biomolecule in the cytosol. This step is critical for nucleic 
acid delivery to increase the possibility of nuclear transport and the ultimate expression of the 
delivered genes (Bareford and Swaan, 2007). 
1.4.2. EGF receptor targeted delivery systems  
The epidermal growth factor receptor (EGFR, ErbB) is a 170 kDa protein that is distributed 
randomly on the surface of cells, excluding hematopoietic cells. Its ligand, EGF, is a 53 
aminoacid-peptide that mediates cellular signal events regulating cell proliferation, 
differentiation, cell cycle progression, adhesion, invasion, angiogenesis and inhibition of 
apoptosis. Following binding of the EGF, the EGFR functions either as a homodimer through 
the complexation of two identical EGFR molecules or as an heterodimer by associating with 
one of the three other ErbB family members; in either case the resulting dimerization then 
initiates the cellular internalization (Bublil and Yarden, 2007). 
The EGFR is a tempting target for gene delivery since it is overexpressed in a wide variety 
of human tumors found in cancers of head and neck, breast, colon, ovary, lung, prostate 
and liver (Johnston et al., 2006). Enhanced EGFR expression is associated with tumor 
invasiveness, resistance to chemotherapy and radiation therapy and clinically correlates with 
poor prognosis and lower patient survival (Rubin Grandis and V. A.; Wagener, 1998). 
Squamous cell carcinoma of the head and neck is a cancer commonly associated with 
EGFR overexpression (>90%), which appears to play a role in the unregulated growth of these 
cells (Cohen, 2006). EGFR has been used to target drugs and toxins loaded in therapeutic 
liposomes (Kullberg et al., 2003; Mamot et al., 2005) and lipoplexes (Shir et al., 2006). 
1.5. Fluorescent nanoparticles in live-cell imaging 
1.5.1. Applications for lipid-based delivery systems  
The use of multifunctional nanoprobes for molecular and cellular imaging is already 
showing great promise, providing new insights into approaches such as gene therapy and 
drug delivery. 
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 Underlying the rational design of gene or drug loaded delivery vectors is the recognition 
of the individual steps of a particular internalization pathway. Live-cell imaging and single-
particle tracking using confocal fluorescence microscopy have shed light on the intracellular 
dynamics and bottlenecks of the drug/gene delivery process (Payne, 2007; Zhang et al., 
2007).  
1.5.2. Long-term imaging using Quantum Dots 
Continuous cell imaging has been dramatically improved with the introduction in the last 
decade of fluorescent probes such as Quantum Dots (QDs), colloidal nanocrystals with 
unique optical properties that make them outstanding fluorescent labels for long-term and 
multicolor imaging (Alivisatos et al., 2005; Michalet et al., 2005).  
QDs commonly consist of a cadmiumselenide (CdSe) or cadmiumtelluride (CdTe) core 
enclosed within a zincsulfide (ZnS) passivation shell. The cadmium-based core is toxic to cells, 
but the ZnS shell isolates it from the cell rendering the core non-toxic at functionally useful 
concentrations. Peptides, polyethylene glycol (PEG) or other biocompatible polymers, also 
provide protection and specific sites for bioconjugation (Figure 1.5, left top panel).  
The main advantages of QDs over organic fluorophores are the greater photostability and 
the excitation wavelengths range that extends above 500 nm. This latter feature reduces cell 
phototoxicity, essential for long-term fluorescence imaging. Because the molar extinction 
coefficients (0.5–2 × 106 M–1cm–1) of QDs are about 10–50 times larger than those of organic 
dyes, the QDs absorption rates will be 10–50 times greater than those of organic dyes at the 
same excitation photon flux. Because of the corresponding increased rate of light emission, 
single QDs appear 10–20 times brighter than organic dyes (Li et al., 2007). Furthermore, the 
emission wavelengths of QDs are size-tunable (Figure 1.5, left bottom panel). For example, 
QDs of approximately 2 nm in the core diameter produce a blue emission, whereas QDs of 
approximately 7 nm in diameter emit red light. Therefore, multiple colors QDs can be 
generated by controlling the size of the nanoparticle during the synthesis. Although QDs 
absorption spectra are broad, emission spectra are narrow (Figure 1.5, right panel) without 
the extension to the red characteristic of organic dyes. This feature allows for simultaneous 
detection of multiple color QDs upon illumination with single light source (Smith et al., 2004). 
Despite these features, QDs biocompatibility remains a critical issue to use in humans and 
a possible limitation to their in vivo applications (C. Kirchner and H.E. Gaub, 2005). 
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Figure 1.5: Scheme of Quantum Dots nanoparticles. Left top panel: QDs of CdSe core are 
surrounded by a ZnS shell and coated with biocompatible polymers. Left bottom panel: Size-tunable 
fluorescence emission. Right panel: Absorption (upper curves) and emission (lower curves) spectra of 
four CdSe/ZnS QDs samples. The blue vertical line indicates the 488-nm line of an argon-ion laser, which 
can be used to efficiently excite all four types of QDs simultaneously. Adapted from (Daniele Gerion, 
2001). 
1.5.3. Ligand tagged Quantum Dots 
 QDs have to be functionalized to act as useful, specific fluorescent labels. The targeting 
moiety attached to the QD surface determines the mode of entry into cells and their 
intracellular localization. Selective staining of plasma membrane and intracellular organelles 
was achieved using QD-labeled antibodies, receptor ligands or targeting peptides (Figure 
1.5, left top)(Michalet et al., 2005; Al-Jamal and Kostarelos, 2007). Dynamic processes such as 
diffusion of membrane receptors (Dahan et al., 2003) or antigen uptake by cells (Cambi et 
al., 2007) have been tracked with ligand and antigen tagged QDs, respectively. 
The cell binding of EGF tagged QDs has been extensively investigated in the laboratory in 
which this thesis work was carried out. It has been demonstrated that complexes of 
streptavidin-conjugated quantum dots (QDs) with biotinylated EGF are biochemically 
competent ligands for erbB1, the EGF receptor (Lidke et al., 2004). The application of 
multicolor EGF-QDs allowed tracking endocytosis of the receptor-ligand complex to follow 
subsequent steps in time. Figure 1.6 (A,B) shows two different colors of ligand-QDs delivered 
sequentially to identify early and late endosomes (Lidke et al., 2007). In addition, a previously 
unreported retrograde transport of activated erbB1 receptors on cellular filopodia was 
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detected at the single molecule level (Lidke et al., 2005). QDs allowed the visualization of the 
displacement of EGF-EGFR complexes on filopodia towards the surface and the interior of 
living A431 cells (Figure 1.6 (C,D). 
 
 
Figure 1.6: Tracking of endosomes with two different color QD-EGF complexes. A: QD605-EGF added 
to A431 cells, incubated RT for 3 min, washed and incubated for 5 min at 37° C, then QD525-EGF  were 
added and images acquired for 8 min at 37° C. Early endosomes: red only whereas QD525-EGF is 
predominantly external. B: QD525-EGF washed and observed 20 min later at 37° C. Several classes of 
endosomes containing red only, green only or both QD colors (see inset). Early, sorting and late 
endosomes are loaded (Lidke et al., 2007). Retrograde transport visualized with single EGF tagged QD. 
C: Selected frames of an A431-erbB1-GFP cell (green) from a time series after binding 5 pM EGF-QD 
(red) followed by addition of free EGF (50 ng/ml) at 300 s. Wide field image, scale bar is 5 μm. Images 
arecontrast enhanced. D: Trajectory of the indicated monomer erbB1-EGF-QD complex (yellow arrow) 
on a filopodium that exhibits random diffusional movement (black) until the addition of unlabeled EGF 
(green box), after which the complex exhibits active retrograde transport (red). Adapted from (Lidke et 
al., 2005). 
 
The recent advances in the chemistry of QD coating permit the simultaneous conjugation 
of two or more different molecules, and thus, the simultaneous stimulation of several 
receptors, further broadening the potential applications of these fluorescent probes for 
dynamic studies of cellular processes (Xiaohu Gao, 2004). However, the existence of multiple 
groups on the surface of QDs can be considered a disadvantage in comparison to single 
attachment sites or reactive entities. In fact, a high number of molecules contributing with 
multiples sites of conjugation leads to a distribution of QDs subpopulations differing in 
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particle-label stoichiometries and undesirable cross-linking. Procedures for achieving precise 
control of the number of sites have been developed (Sperling, 2006; Lidke et al., 2007). 
Multiple sites can be advantageous for multifunctionality, for instance, the combination of 
targeted QDs and lipid carriers in a single nanoparticle can serve to elucidate the 
internalization route, fate of carriers and processing of therapeutic drugs. The attractiveness 
of such hybrid nanoparticles are: 
 Lipid carrier and QDs can be surface functionalized with a ligand for specific 
targeting 
 Complexes of drug-QDs can be encapsulated in the lipid carriers improving QDs 
biocompatibility and providing a therapeutic effect 
 The fluorescent lipid vehicle can be tracked continuously 
 Combining two colors QDs on the surface and inside the lipid vesicle, the fate of 
the carrier and the loaded drug could be followed independently 
1.6. Aims and organization of the thesis  
A new emerging field in targeted delivery is the multi-modality carrier, in which a 
therapeutic molecule, an imaging agent or a fluorescent probe and a targeting entity are 
assembled in a single nanometer-scaled scaffold for simultaneous imaging and therapy.  
The aim of this thesis was to develop a QD labeled and EGFR targeted delivery system 
mediated by Biotinylated Lipid Particles (BLP). 
The human epidermoid carcinoma cell line A431 was chosen because of its large 
overexpression of EGFR, approximately 106 receptors per cell. 
The original approach proposed here was not only the specific targeting but the novel 
encapsulation of QDs in these lipid particles by a detergent dialysis technique. A dual-color 
labeling strategy with loaded and surface bound QDs was introduced to follow the 
intracellular localization of the cargo and carrier by confocal microscopy. 
EGFR targeted and QD labeled BLP were loaded with plasmid DNA and cell specificity 
and transfection efficiency of the delivery system were evaluated according to the 
expression of the GFP reporter gene.  
Finally, a DNA labeling strategy was conceived to achieve sequence specific and non-
covalent labeling of DNA using a single QD and bis-peptide nucleic acids (bis-PNA). The 
objective was to obtain a transfection competent and labeled DNA cargo for the 
developed BLP. 
The specific objectives were: 
 Create a functional ligand-QDs labeled BLP 
 Demonstrate enhanced receptor-mediated uptake of the complex and gene 
expression 
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 Develop the imaging methodology to follow intracellular localization of lipid particles 
and cargo by confocal microscopy 
 Design a  QD-PNA-DNA complex for cellular imaging of DNA in delivery systems 
The results obtained in this study are divided in three sections. The first one describes the 
preparation of biotinylated liposomes (BLP) with encapsulated DNA or Quantum Dots, and 
the physicochemical characterization of the particles according to size, biotinylation and 
DNA or QDs encapsulation efficiency. 
The second section presents the EGF-based targeting strategy of the BLP either loaded 
with DNA or QDs and then focuses on the cell binding experiments. A two-color BLP labeling 
strategy usign QDs was designed, where colocalization of green emitting QD525 and red 
emitting QD655, allowed the immediate recognition of targeted BLP during live cell imaging 
by confocal microscopy. 
 The specificity for the EGF receptor was examined in a competitive binding assay in the 
presence of excess ligand EGF and after incubation of BLP with cell lines devoid of the 
receptor. 
Transfection competencies of EGFR-targeted and DNA loaded BLP particles were 
evaluated as the percentage of cells expressing GFP compared to cells incubated with non-
targeted particles. 
The third section presents the non-covalent DNA labeling strategy using bis-PNA and a 
single QD per plasmid and describes the characterization of the labeled complexes by gel 
electrophoresis and Atomic Force Microscopy. The data, although preliminary, are 
complementary to the main results of this thesis and represent the first steps towards a QD-
labeled plasmid that could be monitored along the pathway to the nucleus. Such a labeled 
plasmid appears as an attractive cargo for the BLP. 
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2.1. Reagents 
2.1.1. Lipids 
Lipids were purchased from Avanti Polar Lipids (Alabaster, USA) and from Northern Lipids 
(Vancouver, Canada) as lyophilized powders or dissolved in chloroform. Chemical structure 
and nomenclature are depicted in Table 2.1. Lipids were stored under argon in a desiccator 
at -20 °C. 
 
Description Nomenclature Chemical structure 
Phospholipid 
DOPE 
1,2-Dioleoyl-sn-Glycero-3-
Phosphoethanolamine 
 
Cationic lipid 
DOTAP 
1,2-Dioleoyloxy-3-
trimethylammoniumpropane 
chloride 
 
Biotinylated 
lipid 
Biotin-PEG-DSPE 
1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-
[Biotinyl (Polyethylene 
Glycol) 2000] (Ammonium 
Salt) 
 
PEG-
modified 
ceramide 
PEG-Cer-C20 
N-Arachidoyl-Sphingosine-1-
[Succinyl (Methoxy 
(Polyethylene Glycol) 2000)] 
 
PEG-
modified 
ceramide 
PEG-Cer-C8 
N-Octanoyl-Sphingosine-1-
[Succinyl (Methoxy 
(Polyethylene Glycol) 750)] 
 
pH-sensitive 
lipid 
PEG-DSGS 
3-O-[2’-(omega-
monomethoxy (Polyethylene 
Glycol) 2000) succinoyl]-1,2-
Distearoyl-sn-Glycerol 
 
 
Table 2.1: Synthetic lipids used in the formulation of lipid particles. 
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Chloroform, Ethanol, Methanol, Isopropanol and Water HPLC quality were purchased from 
Merck. 
Buffers were prepared with analytical grade chemicals. Detergent, Triton X-100 was 
purchased from Fluka, detergent 1-o-n-octyl-β-D-glucopyranoside (OGP), sucrose, HABA 4-
Hydroxyazobenzene-2-carboxylic acid) and kanamycin from Sigma and nonpolar 
polystyrene adsorbents Bio-Beads SM-2 from BioRad.  
UltraPure™ Agarose was purchased from Invitrogen. 
Luria Bertani (LB) medium in powder form was obtained from Difco. 
2.1.2. Biotin and biotin-related reagents 
Biotin and Biocytin were purchased from Sigma, Ez link Sulfo NHS-LC-LC-Biotin and EZ-Link 
PEO-Biotin Dimer (+)-Biotinyl-hexaethyleneglycol dimmer from Pierce.  
Biotin-EGF and EGF (human recombinant) were obtained from Molecular Probes. 
2.1.3. Buffers 
Hepes buffered saline (HBS): 10 mM HEPES (2-hydroxyethyl)-1-piperazine ethanesulphonic 
acid, 150 mM NaCl (sodium chloride), pH 7.4. 
Hepes-Mg buffer: 10 mM HEPES (2-hydroxyethyl)-1-piperazine ethanesulphonic acid, 5 mM 
MgAc2 (Magnesium Acetate), 10 mM KCl pH 7.4 prepared with Ultrapure Water HPLC quality 
and filtered through 0.02 µm pore size.  
Phosphate buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 7.9 mM Na2HPO4,1.5 mM 
KH2PO4, pH 7.3. 
Tyrode’s buffer: 135 mM NaCl, 10 mM KCl, 0.4 mM MgCl2, 1 mM, CaCl2, 10 mM HEPES, pH 
7.2.  
20 mM Glucose and 0.1% BSA were added before use. 
10 mM Sodium Acetate buffer pH 5.2: 1g/l Sodium acetate tri-hydrate and 0.16 g/l acetic 
acid (glacial). 
50X TAE: 242 g Tris base, 57.1 g glacial acetic acid, 100 ml of 0.5 M EDTA, pH 8.0. 
2.1.4. Quantum Dots 
Streptavidin-coated QDs (StAv-QDs) with maximum fluorescence emission peaks at 525 
nm (StAv-QD525), 605 nm (StAv-QD605) and 655 nm (StAv-QD655) and ITK-carboxyl QD655 were 
purchased from Invitrogen. 
2.1.5. Labeled proteins  and organic fluorophores 
Streptavidin Alexa Fluor488 (ex. 488 nm/em. 519 nm), Transferrin Alexa Fluor488 , Sybr Green 
(ex. 495 nm/em. 521 nm), Cy5 NHS ester (ex. 650 nm/ em. 670 nm) and Hoechst 33342 (exc. 
365 nm/ em. 455 nm) were purchased from Molecular Probes. 
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2.1.6. Plasmid DNA  
Plasmid pEGFP-C1, 4.7 Kb encoding the Enhanced Green Fluorescent Protein (EGFP: ex. 
488 nm/em. 507 nm), was bought from Clontech Laboratories (Heidelberg, Germany). This 
encodes a red-shifted variant of the wild-type green fluorescence protein. 
2.1.7. bis-PNA (bis Peptide Nucleic Acid) 
bis-PNA (bis- Peptide Nucleic Acid) MW: 5655 (ε260 nm= 107840 M-1cm-1) was acquired from 
Oswel, Southampton, UK.  
bis-PNA sequence: NH2-LL-TCCCCCTTT-LLL-TTTCCCCCT-LL, where L represents 8-amino-3,6-
dioxaoctanoic acid. 
bis-PNA anchoring sequence in p-EGFP C1 plasmid: AGGGGGAAA at base pair position 
4515-4523.  
2.1.8. Restriction endonucleases and DNA standards 
Restriction endonucleases Apa LI, Ava II and Ase I and the corresponding buffers were 
obtained from New England Biolabs. DNA markers of 100 bp and 1 Kb were from Invitrogen. 
2.2. Cell lines, media and labware 
Human epidermoid carcinoma cell line A431 and CHO (Chinese hamster ovary) cell line 
were obtained from the American Tissue Culture Collection, while the melanoma cell line 
WM983A, was kindly provided by Prof. Meenhard Herlyn (Wistar Institute, Philadelphia, PA). 
Dulbecco’s Minimal Essential Medium was obtained from Gibco. Leibovitz’s L15 medium 
was from Mediatech, Inc. FBS was bought from PAN. Penicillin and Streptomycin and Trypsin 
were purchased from Gibco. EDTA, BSA and glucose were from Sigma.  
Paraformaldehyde (PFA) of analytical grade was freshly prepared as a 4% solution in PBS 
for cell fixation. 
Glass coverslips 12 mm were acid washed and sterilized. LabTek 8-well or 2-well glass 
chambers, plastic cell culture dishes and flasks were purchased from Nunc or Sarstedt. 
2.3. Miscellaneous 
 Ultraconcentrators 3 kDa and 10 kDa cut-off, Amicon (Millipore), Vivaspin (Viva Science 
Sartorius, Göttingen)  
 Gel filtration columns Sephacryl-HR 200 and HR-400 and Superdex™ 75 /Superdex™ 200 
(GE Healthcare) 
 Native 3-8 % Polyacrylamide precasted gels (Invitrogen) 
 Dialysis Cassettes, Slide-A-Lyzer, 10 kDa cut-off for 0.5-3 ml sample, (Pierce) 
 Streptavidin-coated magnetic beads Dynabeads M-280, (Dynal Biotech) 
 Thin-wall polypropylene centrifuge tubes 2.5 ml (Beckman) 
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 Filters set for fluorescence microscopy (Chroma and Omega) 
 Silicon Nitride ultrasharp cantilevers for AFM (Veeco and Mikromarsch) 
2.4. Equipments and softwares 
Bench top centrifuge Mini spin plus (Eppendorf) 
Centrifuge Beckman Avanti J-25 
Ultracentrifuge/rotor with swinging 
buckets 
TL-100/TLS 55 Beckman 
Chromatographic system 
SMART, Pharmacia Biotech, GE Healthcare Life 
Sciences 
Laser-based scanning system for 
fluorescence detection 
Typhoon, Amersham Biosciences 
UV-Vis spectrophotometer Cary 100 Scan 
Fluorescence spectrophotometer Varian Cary Eclipse 
Particle analyzer Zeta Sizer Nano ( Malvern Instruments) 
Atomic Force Microscope  Nanoscope IIIa Multimode AFM (Veeco) 
Electron microscope Philips CM 12 
Optical microscopes  
Axiovert 100 (Zeiss, Göttingen, Germany) 
 Olympus IX71 
iXon CCD camera for microscopy Andor technology 
Laser Scan Confocal Microscope LSM 510 Meta (Zeiss, Göttingen, Germany) 
Flow cytometer Coulter Epics 
Software for Image analysis and data 
handling: 
AFM analysis: Vision 700  
Image analysis:  
Image J free software for microscopy 
DIPImage toolbox in Matlab 7.01 
Flow cytometry analysis: Reflex software 
 
 
Nanoscope v. 7.00. (Veeco) 
 
(http://rsb.info.nih.gov) 
(http://www.ph.tn.tudelft.nl/DIPlib/index.html) 
(http:// www.freewebs.com/cytoflex) 
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2.5. Preparation of Biotinylated Lipid Particles (BLP) 
As depicted in the diagram below (Figure 2.1), to prepare 1 ml of BLP formulation, 8.4 
µmols DOPE (neutral lipid), 0.6 µmols DOTAP (cationic lipid) and 0.024 µmols Biotin-DSPE were 
initially mixed in 2 ml glass vials.  In individual vials containing this lipid mixture, different 
micromolar amounts of PEG-lipids (Table 2.1) were added to obtain 1.4, 2.7 and 10 (mol%) 
PEG content and a final lipid concentration of ~10 mg/ml in the BLP formulation. These 
solutions were dried with a stream of argon and residual chloroform was removed under 
vacuum overnight.  
 
 
 
Figure 2.1: Flow diagram of BLP preparation with encapsulated plasmid DNA or QDs.  
2.5.1. Detergent dialysis technique  
The resulting lipid film was hydrated in 0.5 ml of HBS containing 100 µl of 1M OGP 
detergent with continuous magnetic stirring at 60 °C to favour complete dissolution. For the 
preparation of BLP with encapsulated DNA (BLP-DNA), the detergent dialysis technique 
described by (Hofland et al., 1996) was applied with modifications. In this approach, 100 µg 
or 200 µg peGFP-C1 plasmid (purified as described in 2.10.1) were diluted in 0.5 ml HBS and 
added with stirring to the solubilized lipids-detergent solution (0.5 ml). The mixture was kept at 
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RT for 30 min and followed by a dialysis at RT against HBS using a 10 kDa MWCO membrane 
for 2-3 h or until turbidity was noticeable. Then, the dialysis was continued in a cold room (~4 
°C) overnight and after two buffer changes of 1 l HBS, residual detergent OGP was removed 
by adding polyestyrene SM2 Biobeads (adsorbent capacity ~117 mg OGP/g beads). Control 
BLP samples without plasmid were prepared in parallel. 
In order to prepare BLP with encapsulated QDs (BLP-QDs), ITK-carboxyl QD655 were added 
to the corresponding lipid-detergent mixture in HBS (50 nM final QDs concentration). Samples 
were immediately dialysed as described for BLP-DNA particles. 
2.5.2. Ultracentrifugation in sucrose density gradient 
In order to separate and recover DNA and QDs loaded BLP from less dense empty BLP 
and non encapsulated material, the samples obtained after the detergent dialysis were 
loaded on top of a discontinuous sucrose density gradient. 
The sucrose gradient was prepared in 2.5 ml Beckman ultraclear thin-wall centrifuge tubes 
by carefully applying with a tip or syringe, layers of 0.6 ml 2.5 %, 10%, and 20% (w/v) sucrose in 
HBS (Mok et al., 1999). The BLP samples recovered from the detergent dialysis were adjusted 
to 1% (w/v) sucrose density and were added on top of the gradient. Ultracentrifugation was 
carried out for 5 h at 160,000 g at 10 °C in a TLS-55 rotor with swinging buckets.  
The resolved turbid bands from BLP-DNA samples were carefully recovered and, together 
with aliquots of the gradient, were analyzed for particle size, biotin content and DNA 
encapsulation efficiency. 
Centrifuge tubes containing BLP-QDs samples were briefly illuminated with UV light to 
detect QD655 fluorescence, and consequently the location of QDs containing bands. 
Fluorescent bands were analyzed by TEM at the Electron Microscopy Department of the 
institute. 
2.5.3. Particle size analysis by Dynamic Light Scattering 
The mean hydrodynamic diameter of the obtained BLP was measured by Dynamic light 
scattering (DLS) which involves the determination of how the intensity of the light scattered 
by a solution of moving particles varies with time. This variation is correlated with the speed at 
which particles move, which can be characterized by their diffusion coefficients (Pecora 
and Aragon, 1974). The hydrodynamic diameter d of particles is obtained from the diffusion 
coefficients D, according to: 
 d = 
kT 
3π η D 
 
where, k is the Boltzman constant, T is the temperature and η is the solvent viscosity. 
DLS measurements were performed with a NanoZetasizer from Malvern Instruments, 
detecting the back scattered light from a 633 nm laser at a fixed angle of 173°. 
2. Materials and methods 
 29 
Samples were diluted in PBS and the measurements performed at RT. The PBS used to 
dilute the samples was previously filtered through 0.02 µm pore size to eliminate potential 
interfering impurities. 
The operating protocol was chosen for spherical particles, applying 12 to15 runs per 
measurement, which were automatically selected according to the concentration of 
particles in the sample, and three measurements were performed on each sample. The 
autocorrelation function for size distribution was calculated using the CONTIN mathematical 
approach for heterodisperse, polydisperse and multimodal systems (Provencher, 1982). 
The mean hydrodynamic diameter obtained represents only an intensity-based average 
value and does not give any information on the prevailing size distribution. For this reason, the 
polydispersity index (pdi) is also stated to give information about the actual distortion of a 
monomodal distribution. The pdi can have values between 0-1 and is equivalent to the 
variance σ2 of the size distribution. Samples with pdi <0.25 are considered as monodisperse 
solutions. 
2.5.4. DNA quantitation 
The amount of plasmid recovered and encapsulated after dialysis and ultracentrifugation 
in sucrose density gradient was quantitated using the Sybr Green fluorescence assay (Zhang 
et al., 1999). In the presence of DNA, the dye binds specifically to double-stranded DNA and 
emits at 522 nm. Briefly, 25 μl aliquots of standard solutions varying from 0-5 µg/ml plasmid 
DNA or dilutions of BLP were mixed with 25 μl of HBS buffer containing 0.5 μg/μl Sybr Green 
solution. Sybr Green fluorescence was excited at 495 nm and emission spectra were 
collected from 505 to 700 nm with a slits width of 10 nm for both excitation and emission. 
The plasmid DNA content in BLP formulations was calculated from the linear curve fitting 
obtained after plotting the maximum fluorescence intensity (a.u.) of Sybr Green at 522 nm as 
a function of DNA concentration in µg/ml plasmid (Figure 2.2). 
 
 
 
Figure 2.2: Representative DNA calibration curve using Sybr Green dye. Sybr Green excited at 495 
nm and emission recorded from 505-700 nm. Maximum fluorescence intensity (a.u.) at 522 nm was 
plotted as a function of plasmid DNA concentration. Data correspond to three curves obtained in 
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independent experiments. Each point is an average of duplicates. Free Sybr Green is non-fluorescent in 
HBS (0 µg/ml plasmid DNA). The presence of 0.1% Triton-X100 did not change the maximum 
fluorescence intensity at 522 nm of Sybr Green upon DNA binding (not shown). 
 
Free or exposed plasmid DNA was quantitated directly in BLP solutions. Then, lipid particles 
were solubilized with 0.1% Triton X-100 and total DNA content was measured. The obtained 
value was related to the initial amount added to compute DNA encapsulation efficiency. 
2.5.5. Biotin quantitation  
The biotin content of BLP was determined on samples recovered after detergent dialysis 
and ultracentrifugation in sucrose gradient.  
The fluorometric assay used is based on Foster resonance energy transfer (FRET) (Batchelor 
et al., 2007), providing high sensitivity to detect nanomolar concentrations of biotin linked to 
proteins or nucleic acids. In this assay (Figure 2.3A), the Alexa Fluor488-streptavidin conjugate 
(StAv-Alexa488) acts as FRET donor and the dye HABA as a quencher, occupying the biotin 
binding sites of the dye-labeled streptavidin. In the absence of biotin, HABA quenches the 
fluorescence emission of the Alexa Fluor488 dye via FRET. When biotin or a biotinylated 
molecule is added, HABA is displaced from the biotin binding sites resulting in an increase in 
the donor fluorescence intensity proportional to the amount of biotin present in the sample.  
The standard curve of biocytin, a water-soluble biotin analogue, was obtained by titrating 
a solution containing 25 nM StAv-Alexa488 and 125 μM HABA in HBS. Biocytin was added from 
an aqueous stock solution to give final concentrations of 0–200 nM in 50 μl samples. 
Fluorescence of standards and samples was measured in a spectrofluorometer, Alexa Fluor488 
dye was excited at 485 nm and emission spectra were collected between 500-700 nm.  
The fluorescence intensity at the emission maximum (519) nm was plotted as a function of 
biocytin concentration (nM) and the data were fitted to a sigmoid curve to obtain the 
corresponding values for the unknown samples (Figure 2.3B). In the conditions assayed a ~6-
fold increase in fluorescence signal upon complete displacement of HABA was observed 
with a detection limit of approximately 3 nM biocytin (Figure 2.3C). 
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Figure 2.3: Fluorometric assay for biotin quantitation. A: General scheme of the assay adapted from 
(Batchelor et al., 2007). HABA acts as acceptor of Alexa Fluor488 fluorescence while bound to biotin 
binding sites. When biotin or biocytin is added, HABA is displaced and the fluorescence signal of Alexa 
Fluor488 increases. B: Biocytin standard curve obtained by titrating a solution containing 25 nM StAv-
Alexa488 and 125 μM HABA in HBS. At least 8 values were obtained to plot the data within a biocytin 
range of 0-200 nM. Excitation of Alexa488 at 485 nm and emission collected from 500 to 700 nm. The 
data illustrate a ~6-fold increase in fluorescence signal upon complete displacement of HABA. 
According to manufacturers, three biotin-binding sites are available per streptavidin molecule 
corresponding to 75 nM biotin binding sites C: The detection limit achieved was approximately 3 nM 
biocytin. 
2.5.6. Transmission Electron Microscopy  
The size and morphology of BLP and encapsulated QDs were analyzed by TEM by Dr. 
Dietmar Riedel in the Electron Microscopy department at the MPIbpc.  
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2.6. Labeling and targeting of BLP 
2.6.1. EGF-QDs preformed complexes  
The formulation of the streptavidin conjugated QDs includes a polyethylene glycol 2000 
(PEG) outer layer to which 6-8 streptavidin molecules per QDs are covalently linked. This 
allows variations in the stoichiometry of the ligand-QD complexes. Procedures for binding 
biotinylated ligands to commercial streptavidin conjugated quantum dots were optimized in 
our lab and detailed protocols are described in (Lidke et al., 2007).  
Biotin-EGF were coupled to StAv-QD525 (or QD605) at ratio 2:1 or 4:1 in HBS with 0.2% BSA at 
50 nM QDs final concentration. Solutions were incubated at 15 °C for at least 30 min with 
gentle agitation before coupling to BLP. 
2.6.2.  EGF-QDs coupling to BLP 
BLP loaded with QD655 or plasmid DNA were incubated with preformed complexes of EGF-
QD525 (1:1 v/v) in HBS suplemented with 0.2% BSA. Final concentration of QD525 was 25 nM 
whereas final biotin concentrations on BLP varied from 0.2-10 µM biotin. This mixture was 
incubated for at least 2 h at 15 °C with continuous shaking. 
Separation of EGF-QDs-BLP from EGF-QDs could not be achieved by size exclusion 
chromatography or sucrose gradient (data not shown) and resulted in considerable sample 
loss. Therefore, upon incubation with cells, residual free preformed complexes (EGF-QDs) 
were expected to bind to EGF receptors (Lidke et al., 2004) being indistinguishable from the 
targeted particles (EGF-QD–BLP). In order to solve this problem, two-color BLP labeling 
strategies were designed for BLP either loaded with QDs (Figure 2.4A) or plasmid DNA (Figure 
2.4B).  
 
 
 
Figure 2.4: EGF tagged and two-color labeled BLP. A: with encapsulated carboxyl-QD655. B: with 
encapsulated plasmid DNA. 
 
In the case of BLP-DNA (Figure 2.4B), particles were incubated first with EGF-QD525 in HBS 
supplemented with 0.2% BSA for 30 min at 10 °C. Then, the non-targeted StAv-QD655 were 
added to the EGF-QD525-BLP particles, and incubation proceeded for at least 2 h at 10 °C 
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before in vitro cells experiments. The final concentration of both StAv-QDs was 25 nM 
whereas the final concentration of encapsulated DNA varied among preparations and is 
stated in each experiment.  
In both approaches, the green emitting StAv-QD525 are the ones targeted to the EGFR in 
A431 cells, whereas the red emitting QD655 without the ligand, serve to track the BLP 
themselves. 
2.7. Live-cell experiments 
2.7.1.  Cell culture  
A431 and CHO cell lines were cultured in Dulbecco’s Minimal Essential Medium (D-MEM) 
supplemented with 10% fetal calf serum (FCS), 50 U/ml of penicillin and 50 U/ml of 
streptomycin. WM983A cells were grown in three parts DMEM and one part Leibovitz’s L15 
medium supplemented with 10% heat inactivated (56 °C for 20 min) FCS and Pen-Strep. All 
cells were grown as a monolayer at 37 °C in a humidified atmosphere containing 5% CO2. For 
microscopy experiments, cells were seeded one or two days in advance onto 12-mm-
diameter glass coverslips and employed at a 40-50% confluence. For binding experiments, 
cells were starved in serum free DMEM for 4 h prior to the incubation with BLP to reduce 
signaling induced by growth factors present in the serum. 
2.7.2. Experimental conditions for the incubation of A431 cells with BLP 
Two-color QDs labeled, EGFR-targeted and non-targeted BLP-DNA or BLP-QDs were 
diluted in 200 or 500 µl Tyrode buffer with 0.5% BSA, to obtain 0.5 nM QD525 and 2 nM EGF final 
concentration. Preincubation of targeted and non-targeted BLP with starved A431 cells was 
carried out first at 15 °C, a temperature non-permissive for endocytosis. This preincubation 
time was varied from 5 to 30 min, then cells were warmed at 37 °C and were incubated from 
10 min to 2 h. Finally, unbound BLP were removed and cells washed with Tyrode’s buffer. 
Confocal fluorescence microscopy was performed on live cells immediately after 
removing the complexes and after 30 min and 1, 2, 4, 12, 24 and 48 h incubation at 37 °C. 
When incubation was extended for more than 1h after removing the BLP, Tyrode’s buffer was 
replaced by complete DMEM. 
2.7.3.  Incubation of EGF-QDs and Transferrin-Alexa488 complexes with A431 cells  
A431 cells were grown on glass coverslips at a density 40-50 % and serum-starved before 
experiments. Transferrin-Alexa Fluor488 (60 nM) and EGF-QD605 complexes (2 nM) were added 
to the cells to allow simultaneous internalization. Incubation with the complexes at 37 °C 
proceeded for 10 and 30 min.  
In a second experiment, EGF-QDs complexes were added first to the cells and after 2 h 
incubation at 37 °C, Transferrin-Alexa Fluor488 complexes were added for 5 min. Then, 
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complexes were removed and the cells rinsed and fixed in 4% paraformaldehyde for 15 min 
on ice to prevent redistribution of the QDs. After fixation, coverslips were mounted in PBS for 
confocal microscopy.  
QD605 and Alexa Fluor488 were excited with the 488 nm laser line and the emission collected 
with 565-615 nm and 520-30 nm BP filters, respectively. When QD655 were employed, they were 
excited with the 532 nm line and the emission was collected through a 650 nm LP filter.  
2.7.4.  Competitive binding assay 
Free ligand EGF (recombinant human) was added to starved A431 cells at 200 ng/ml (33 
nM) final concentration and cells were incubated for 10 min at 10 °C to prevent 
internalization. Then, the EGFR targeted BLP (EGF-QD605-BLP-QD655) were added to the cells at 
a final concentration of 2 nM EGF at 10 °C and incubation proceeded at 37 °C for 10 min. 
Cells were rinsed with Tyrode’s buffer and confocal microscopy images were acquired 
immediately in live cells during 60 min at RT. 
The same protocol for applied for binding experiments with excess ligand was carried out 
to test for unspecific binding of EGFR targeted BLP in CHO cell line and WM983A melanoma 
cell line, both devoid of EGF receptor. 
2.7.5. Experimental conditions for targeted gene delivery by BLP 
Cells were seeded in 6-well plates at a density of 0.8-1 x 105 cells per well 24 h prior to 
incubation with BLP-DNA. Starved and non-starved A431 cells were incubated with EGFR- 
targeted and non-targeted BLP-DNA. Since lipid particles with multiple biotins can cause 
aggregation of EGF-QDs, the following two-step protocol was applied to decrease the 
possible cross-linking of BLP and maximize the binding of BLP-DNA to A431 cells: 
1. Preformed complexes of EGF-QD655 (molar ratio 1:4) were added to A431 cells at final 
concentration 0.5 and 2 nM QDs and incubated on ice for 5 min. 
2. Cold BLP-DNA solution containing 1µg plasmid DNA was added for 15-30 min at 15 °C 
to allow binding but not endocytosis. 
Control of non-targeted delivery was carried out by adding cold BLP-DNA (1µg plasmid) 
for 15-30 min at 15 °C to A431 cells without the preincubation with EGF-QD655 complexes. 
After incubation at 37 °C for 10, 30 or 60 min, complexes were removed and the cells 
were washed with Tyrode’s buffer. Incubation proceeded for up to 48 h at 37 °C in complete 
DMEM before analyzing GFP expression by fluorescence microscopy or flow cytometry (see 
section 2.9). 
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2.8. Confocal fluorescence microscopy 
2.8.1. Simultaneous detection of two different colors of QDs 
Scanning confocal fluorescence microscopy is a powerful technique for studying 
dynamic processes in specific intracellular compartments. It is particularly suitable to report 
whether two different probes of interest are physically located in the same compartment. 
Colocalization of labeled molecules can be analyzed by scanning single focal planes along 
the z-axis inside a cell without interference of the out of focus light from other focal planes 
(Chen et al., 2004). Multiple x-y focal planes can be stacked to reconstruct a 3D- image of 
the subcellular region under study. 
Confocal fluorescence microscopy was performed with a Zeiss 510 Confocal Laser 
Scanning microscope using a water immersion objective C-Apochromat 63x/1.2 NA 
(numerical aperture).  
In order to localize the two-color QDs labeled BLP, the simultaneous excitation of QD525 
and QD655 was achieved with the 488 nm laser line, or in some experiments with the 458 nm 
line to increase the fluorescence intensity. QDs signals were simultaneously detected and 
collected in separated channels with appropriate filters, in this case, 520/20 BP for QD525 and 
585 LP for QD655. When QD525 was replaced by QD6o5 in preformed complexes with biotin EGF, 
the QD605 and QD655 were detected using 585-615 BP and a 650 LP filters, respectively. To 
eliminate possible cross-talk when using the same excitation wavelength, single color EGF-
QDs controls were tested for optimization of the gain settings. Time series with single and 
multiple focal planes were acquired with a pinhole set to 1 Airy disc. With the given settings, 
channel cross-talk was negligible as determined using single-labeled samples. For qualitative 
analysis, images were background-corrected before performing brightness and contrast 
enhancement. The same modifications were applied to all samples and controls. Digital 
image analysis was carried out with the free software Image J (http://rsb.info.nih.gov) and 
orthogonal sections were reconstructed using the software provided with the microscope. 
2.8.2. Colocalization analysis 
For quantitative colocalization analysis of QDs in targeted and labeled BLP during binding 
experiments, background was substracted from both QDs channels. The degree of 
colocalization was evaluated by the Pearson’s correlation coefficients estimated according 
to specialized algorithms applied to the images (Costes et al., 2004; Kreft et al., 2004). 
Pearson’s correlation coefficient 
Pearson’s correlation coefficient Rr, is one of the standard measures in pattern 
recognition. In the equation displayed below, S1 represents signal intensity of pixels in the 
channel 1 and S2 represents signal intensity of pixels in the channel 2; S1aver and S2aver reflect 
the average intensities of these respective channels.  
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Rr is used for describing the correlation of the intensity distributions between channels. It 
takes into consideration only similarity between shapes, while ignoring the intensities of 
signals. Its values range between −1.0 and 1.0, where 1.0 indicates significant correlation, 0 
indicates no correlation and −1.0 indicates negative correlation. Negative values of Rr, 
however, should be interpreted very cautiously. 
Colocalization of QD525 and QD655 in dual-labeled BLP was demonstrated by presenting a 
plate of three images, two corresponding to the red (QD655) and green (QD525) channels, 
and a third image where the channels are merged and the overlapping pixels displayed in 
yellow. The distribution of pixels according to channels can be visualized in a two-
dimensional scattergram or correlation plots where the degree of colocalization is described 
by Rr.  
2.9. Quantitative GFP expression analysis 
2.9.1. Epi-fluorescence microscopy 
Conventional epifluorescence microscopy was performed with an Olympus IX71 
microscope equipped with a Plan-Fluor 10X objective and a CCD camera (Andor). The 
following filter sets were applied: 
i. For Hoechst H33342 (ex. 350/50 BP, 400 DM, em. 460/50 BP) 
ii. For GFP (ex. 480/30 BP, 505 DM, em. 535/40 BP) 
iii.  For QD655 (ex. 560/55 BP, 595 DM, em. 655/40 BP) 
Quantitative GFP expression analysis was performed with the DIPimage toolbox for Matlab 
7.01 (http://www.ph.tn.tudelft.nl/DIPlib/index.html). The percentage of cells expressing GFP 
was calculated relative to the total number of cells analized in 20 random microscopic fields. 
These were detected by staining the nuclei with the fluorescent dye bisbenzimidazole 
Hoechst H33342 (1 mM) for 20 min at RT in PBS-BSA buffer.  
The number of cells per field was determined automatically based on the number of 
Hoechst stained cell nuclei (blue). This was carried out by measuring the total blue area (in 
pixels), corresponding to nuclear staining divided by the average nucleus area calculated 
independently for each field. The number of GFP expressing cells was calculated by 
counting the number of blue nuclei colocalized with green cytoplasm and visually inspected 
for control.  
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The input to the algorithm is two images: one with Hoechst-stained cell nuclei and one 
with GFP protein fluorescence. The images were processed as follows: 
In images with Hoescht stained nuclei: 
1. Correction of uneven illumination  
2. Thresholding the blue Hoechst image  
3. Labeling of all spots using connected component analysis 
4. Filtering out spots with an area less than 100 pixels and not round 
5. Finding the mean area of the spots: this will serve as the average area of a single 
nucleus 
6. Division of the total amount of pixels above the threshold (step 2) by the average 
nucleus area to get the total number of cells in the image 
In images with GFP expressing green fluorescent cells: 
1. Suppression of spot-like negatives using elliptic gray-value erosion of width 4 
2. Thresholding the image, marking 10% as passed pixels 
3. Binary erosion of width 4 to suppress poisson noise 
4. Labeling of all spots using connected component analysis 
5. Filtering out of spots with area smaller than twice the average area of the nucleus 
In combined images: 
1.  Finding pixels that are both part of a nucleus (blue) and labeled with GFP (green). 
2. Division of the number of pixels obtained in step 1 by the average area of a single 
nucleus to obtain the number of GFP-expressing cells 
3. Division of the number of GFP-expressing cells by the total number of cells in each 
field analyzed to get the percentage of GFP-expressing cells. 
2.9.2. Flow cytometry 
A431 cells incubated with BLP-DNA (following protocol in 2.7.5) were resuspended with 
Trypsin-EDTA in PBS, fixed in 4% PFA/PBS and the percentage of cells expressing GFP was 
analyzed in a Coulter Epics Elite flow cytometer equipped with a 488 nm argon ion laser.  
GFP fluorescence was excited at 488 nm and emission detected using a 525/40 nm BP 
filter. To discriminate between viable and dead cells and to exclude doublets, cells were 
appropiately gated by forward/side scatter and 10.000 events per sample were collected. 
Further data analysis, subpopulation gating and statistic calculations were performed 
using the software Reflex. 
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2.10. bis-PNA:DNA Hybrids 
2.10.1. Plasmid DNA amplification and purification 
Competent bacterial strain E. coli DH5 was transformed with the pEGFP-C1 plasmid. The 
transformation mix was plated onto a selection agar containing kanamycin 30 μg/ml and 
incubated at 37 °C overnight. A single bacterial colony was picked and inoculated in 2 ml 
LB/kanamycin medium then, incubation proceeded at 37 °C with vigorous shaking for 8 h. 
This culture was afterwards, inoculated into 500 ml of LB/kanamycin and incubated overnight 
at 37 °C with shaking. The bacterial culture was harvested by centrifugation and plasmid 
DNA purified by ion excahnge chromatography using the QiaFilter Plasmid Maxi Kit, 
according to the manufacturer´s instructions.  
2.10.2. Biotinylation of bis-PNA  
bis-PNA sequence, NH2-LL-TCCCCCTTT-LLL-TTTCCCCCT-LL L=8-amino-3,6-dioxaoctanoic 
acid, was biotinylated at the terminal amino group by adding a 20 molar excess of Sulfo 
NHS-LC-LC-Biotin reagent in PBS and incubating for 90 min at RT without removing the excess 
of reagent. Biotin incorporation was 80-90% for three independent preparations measured 
indirectly as the amount of free non-modified amino groups. This was calculated upon 
reacting the free amino groups with the fluorophore fluorescamine (Udenfriend et al., 1972), 
the fluorescence obtained was proportional to the percentage of available amino groups. 
2.10.3. Cy5 labeling of bis-PNA 
Labeling reaction with Cy5 was performed by mixing 5 µM bis-PNA and 50 µM NHS-Cy5 in 
Carbonate buffer 0.1 M pH 8.3, the reaction mix was incubated for 2 h at RT followed by 2 h 
at 4 °C. 
Purification of labeled PNA was performed in a chromatographic system (Smart) using a 
gel filtration column with matrix of dextran Superdex 75 and eluted in 10 mM Acetate buffer 
pH 5. The concentration of the recovered Cy5-bis-PNA was calculated using the extinction 
coefficient of Cy5 at 650 nm, ε650 nm = 250,000 M-1cm-1. 
2.10.4. Hybridization of bis-PNA to pEGFP-C1 plasmid 
Biotin-bis-PNA or Cy5-bis-PNA were hybridized to the anchoring site in pEGFP-C1 plasmid 
at position 4515-4523 (sequence AGGGGGAAA). Biotin-bis-PNA or Cy5-bis-PNA were added 
to 2 µg plasmid in 10 mM Sodium Acetate buffer pH 5 at molar ratios of bis-PNA to plasmid, 
2:1, 4:1, 8:1, 20:1 and 40:1. The mixtures were incubated for 3 h at 37 ºC and hybrids were 
purified from excess labeled or biotinylated bis-PNA using Sephacryl HR-400 spin columns pre-
equilibrated with 10 mM Sodium Acetate buffer pH 5. After sample addition, a centrifugation 
step was carried out for 2 min at 800 g to recover the purified hybrids. Biotin-bis-PNA-plasmid 
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DNA will be referred as biotinylated Hybrids. Purity and quality of the recovered plasmid were 
determined by enzymatic digestion with restriction endonucleases. 
2.10.5. QD labeling of Hybrids  
QD labeled Hybrids were obtained by reacting biotinylated Hybrids (2 nM biotin) with 
StAv-QD655 (2 nM streptavidin) in 50 mM Sodium Borate buffer pH 8.5 for 4h at 4 °C under 
agitation. These complexes will be referred as QD-Hybrids. 
2.10.6. Restriction fragment analysis by gel electrophoresis 
Hybrids were analyzed by digestion of pEGFP-C1 plasmid with the following 
endonucleases: 
Apa LI: Restriction site at position 4360  
Ava II: Restriction sites at positions 1270, 3272, 3717 
Ase I: Restriction site at position 4731 
PNA target site in plasmid: 4515-4523 bp 
Plasmid digestion with Apa LI and Ava II generates restriction fragments of 445 bp, 643 bp, 
1641 bp and 2002 bp. The PNA target site is located in the 1641bp fragment. 
Digestion with Apa LI and Ase I produces two fragments of 379 bp and 4352 bp. The PNA 
target site is located in the 379 bp fragment. 
 
Reaction mix for plasmid digestion 
Plasmid DNA (0.5-1 µg) was incubated with 2 µl 10X buffer NB4**, 1-2 U (Units*) restriction 
enzyme and 1 µg/µl BSA. Milli Q water was added to a final volume of 20 µl and the reaction 
mixture incubated at 37 °C for 1 h. Restriction fragments were analyzed in 1% agarose gels. 
*One unit of restriction enzyme is the amount of enzyme required to completely digest 1 μg substrate 
DNA in 1 hr. 
**NEB 4: 20 mM Tris-acetate (pH 7.9), 10 mM Magnesium acetate, 1 mM DTT, 50 mM Potassium acetate 
 
Agarose gel electrophoresis  
Biotinylated, Cy5 labeled and QDs labeled Hybrids, and restriction fragments were 
electrophoresed in 0.8 or 2% agarose gels in 1X TAE buffer. Electrophoresis was carried out at 
RT under constant voltage (60 V) and gels were protected from direct light exposure. After 
electrophoresis, gels were stained with 0.5 µg/µl Sybr Green solution in 1X TAE to visualize total 
DNA content. Sybr Green, Cy5 and QDs fluorescence were detected in gels with a laser-
based scanner (Typhoon instrument). The laser lines were selected according to the 
corresponding excitation wavelengths of the dyes and fluorescence emission detected using 
a 520/30 nm BP filter for Sybr Green, and a 670 nm LP filter for Cy5 and QD655.  
 
Band shift assay in polyacrylamide gels 
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DNA restriction fragments containing the hybridized biotin-bis-PNA were analyzed in a 
band shift assay in native polyacrylamide gels with a concentration gradient varying from 3-
8% polyacrylamide in 1X TAE buffer. Gels were stained with 0.5 µg/µl Sybr Green solution after 
electrophoresis. 
2.10.7. Conjugation of QD-Hybrids to biotin coated magnetic beads  
QDs-Hybrids were vizualized in biotin coated magnetic beads prepared as follows: 
i. Biotin-coated magnetic beads were obtained by conjugating a biotin dimer, EZ link PEO-
Biotin dimer (200 µM) to streptavidin coated magnetic beads (76 nM streptavidin) in 50 
mM Borate buffer pH 8.0 for 2 h at 4 °C 
ii. Biotinylated Hybrids (20 mM biotin) were conjugated to StAv-QD655 (2 nM QDs and 6-8 
StAv per QD) in 50 mM Sodium Borate buffer pH 8.5 and incubated ON at 4ºC 
iii. QD655-Hybrid complexes were incubated with biotinylated beads for 2 h at RT with 
shaking and protected from light 
iv. Samples were placed in a magnetic stand and beads washed with 50 mM Sodium 
Borate pH 8.5 and incubated with 0.5 µg/µl Sybr Green solution for 5 min 
v. Control samples of biotinylated Hybrids, free QD and free plasmid were incubated with 
streptavidin or biotin coated magnetic beads and then stained with Sybr Green 
vi. Treated beads were washed and resuspended in 50 mM Sodium Borate buffer pH 8.5 
and were deposited on glass coverslips for fluorescence microscopy analysis 
The coupling of Hybrids on magnetic beads was visualized in an inverted microscope Zeiss 
Axiovert 100 equipped with a CCD camera. Sybr Green fluorescence was detected with 
excitation filter 480/30 BP, 505 DM (dichroic mirror) and emission filter 535/40 BP, QD655 
detection: excitation filter 560/55 BP, 595 DM and an emission filter 655/40 BP. The acquired 
images were processed using the DipImage Toolbox from Matlab 7.01. 
2.11. Atomic Force Microscopy analysis 
The Atomic Force Microscope, also called scanned-proximity probe microscopy works by 
measuring a local property of a sample, such as height, with a probe or “tip” placed very 
close to the sample. This results in a three-dimensional profile of the surface that can reach 
atomic resolution on hard flat surfaces. 
Unlike traditional microscopes, scanned-probe systems do not use lenses. Therefore, the 
size of the probe rather than the diffraction effects, generally limits their resolution. Lateral 
resolution of 5 nm and a <0.1 nm resolution in height can be achieved. 
The ’Tapping mode’ of scanning overcomes problems associated with friction, adhesion 
and electrostatic forces by shortly placing the tip in contact with the surface to provide high 
resolution and then lifting the tip off the surface to avoid dragging the tip across the sample 
surface. This mode inherently prevents the tip from sticking to the surface and causing 
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damage during scanning. The AFM can scan the sample under air, vacuum or in a variety of 
fluids where the sample must be previously deposited on a flat substrate, such as mica or 
glass.  
Images of BLP or DNA were obtained with a NanoScope III MultiMode AFM (Veeco 
Instruments Inc., Santa Barbara, CA) operating in tapping mode in air using silicon 
cantilevers. Height and amplitude images were recorded simultaneously and section analysis 
performed using the software available with the instrument. 
2.11.1. Sample preparation for scanning 
For the analysis of BLP morphology, a droplet of lipid particles solution purified from 
sucrose density gradient was deposited on a mica surface and was air-dried before 
scanning. For the QD-Hybrids analysis, samples containing 2 µg/ml plasmid were applied on 
the mica surface pretreated with 2.5 mM MgCl2. After 30 seconds, the mica surface was 
rinsed with water and was gently dried with a flow of nitrogen before AFM scanning. 
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The spontaneous formation of DNA-lipid particles in the neutral detergent octyl-β-D-
glucopiranoside (OGP) was initially described by (Zhang et al., 1997). This method was 
optimized to encapsulate single plasmid molecules with a 50-70% efficiency in particles of 
~70 nm size (Wheeler et al., 1999). The physical characteristics of these particles known as 
SPLP (Stable Plasmid Lipid Particles) appear ideal for in vivo application. However, the 
transfection potency of SPLP is quite limited due to the PEG coating which decrease the cell 
association of SPLP and subsequent uptake. The length of the carbon chain in the PEG-lipid 
directly affects the rate of DNA released from SPLP. For, instance, short acyl chain (C8) in 
PEG-lipids have transfer rates from SPLP in the order of minutes and are referred as to 
exchangeable lipids, whereas PEG-lipids with acyl carbon chain longer than C20 have 
transfer rates of hours or days and are referred as to non-exchangeable lipids (Mok et al., 
1999). 
The approach explored in this thesis involved the addition of a biotinylated lipid (biotin- 
PEG-DSPE) to enhance cell targeting ability by subsequently coupling the EGF ligand via 
streptavidin-biotin interaction. These new liposomes were named BLP (Biotinylated Lipid 
Particles). 
This chapter focuses on the preparation of three different BLP formulations containing 
exchangeable and non-exchangeable PEG-lipids and a pH-sensitive PEG-lipid followed by 
the characterization of the particles according to size, biotin content and DNA/QDs 
encapsulation efficiency.  
3.1. Encapsulation of plasmid DNA and QDs in BLP 
3.1.1. BLP formulations  
Various BLP batches were prepared by mixing DOPE (8.4 mM), DOTAP (0.6 mM) with 
different amounts of the PEGylated lipids. In Table 3.1 are shown the main differences 
between BLP and the original SPLP formulations such as the inclusion of a biotinylated lipid 
(Biotin-PEG-DSGS), a PEGylated pH-sensitive lipid (PEG-DSGS) and ≤10% PEG-lipid content. 
 
PEG-lipid PEG content (mol %) 
 BLP SPLP 
PEG-Cer-C20 10 10 
PEG-Cer-C8 1.4 ; 2.7 ; 10 10-20 
PEG-DSGS 1.4 ; 2.7 - 
Biotin-PEG-DSPE 0.24 - 
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Table 3.1: PEG-lipids composition of BLP compared to SPLP. PEG-Cer-C20 (non-exchangeable PEG-
lipid); PEG-Cer-C8 (exchangeable PEG-lipid); PEG-DSGS (pH sensitive PEG-lipid) and Biotin-PEG-DSGS 
(biotinylated lipid). The final lipid concentration was ~10 mM. 
 
Lipid recovery was estimated from the amount of incorporated biotin-PEG-DSGS after 
detergent dialysis. Biotin content was quantified using a fluorometric assay with nanomolar 
sensitivity. The estimated values of lipid recovery obtained from three independent BLP 
preparations were, 58 ±14 % for BLP loaded with DNA and 65 ±7 % for BLP loaded with QDs.  
3.1.2. Time course formation of BLP during detergent dialysis 
Lipids-detergent solutions prepared with plasmid DNA and control samples without 
plasmid were dialyzed. In the presence of DNA, visible turbidity was detected within the first 
hour of dialysis, suggesting the formation of self-assembled lipid-DNA particles (Zhang et al., 
1997).  
The hydrodynamic diameter of such particles during the course of detergent dialysis was 
measured by DLS. As shown in Figure 3.1A, after 45 min regardless of the presence of DNA, 
particles with a mean hydrodynamic diameter of ~30 nm were detected. This value was 
consistent with the size of mixed micelles of lipids and detergent (Zumbuehl and Weder, 
1981). At this time point, the polydispersity index (pdi) was greater than 0.25, indicating that 
more than one lipid particles population contributed to the intensity of scattered light (see 
below).  After 180 min, control BLP without plasmid achieved their final size with a mean 
diameter of ~50 nm and appeared homogeneous in size (pdi<0.25). On the other hand, in 
the presence of DNA, particles continuosly grew in size up to ∼300 nm during the initial 3 h 
followed by a slight size increase upon vesiculation. 
As stated by pdi values greater than 0.25, the heterogeneity of the samples was 
examined from the size distribution profiles for empty BLP (Figure 3.1B) and DNA loaded BLP 
(Figure 3.1C). In the absence of DNA, the two peaks in the size distribution profile observed 
after 45 min were attributed to mixed micelles and empty BLP. After 360 min, the mixture was 
enriched in particles of homogeneous size of ∼50 nm (Figure 3.1B). 
In the case of lipid-DNA mixtures (Figure 3.1C), the two peaks in the initial bimodal size 
distribution observed after 45 min, probably represent mixed micelles and lipid-DNA particles 
(>1µm). After 360 min dialysis, the bimodal size distribution still persisted but the two peaks 
were centered on ∼60 nm and ~400 nm, indicating the formation of empy BLP and DNA 
loaded particles (BLP-DNA) respectively.   
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Figure 3.1: BLP formation during detergent dialysis. A: Mean hydrodynamic diameter measured by 
DLS after 45, 180, 360 and 600 min of detergent removal. Mixed micelles of detergent and lipids 
coexisted after 45 min dialysis for BLP prepared without plasmid DNA (—) and with 200 µg plasmid DNA 
(—), respectively. Empty BLP achieved their final size after 3 h whereas vesiculation and growth of lipid-
DNA particles continued for up to 6 h. B: Intensity based size distribution of control BLP showing the 
evolution of the initial bimodal distribution into an homogeneous in size BLP population. C: Intensity 
based size distribution of lipid-DNA particles showing the likely coexistence of mixed micelles and lipids-
DNA aggregates after 45 min dialysis. After vesiculation and growth (360 min), the bimodal distribution 
likely represents empty and DNA loaded BLP. Formulation containing 10% PEG-Cer-C20. 
3.1.3. BLP-DNA purification from non-encapsulated DNA 
The detergent dialysis procedure resulted in the formation of a turbid suspension due to 
vesicle formation. However, it was likely that empty vesicles (as shown in Figure 3.1) as well as 
non-encapsulated plasmid were also present. A first attempt to separate BLP-DNA particles 
from free plasmid using anionic exchange chromatography resulted in a significant sample 
loss due to the interaction of BLP with the column matrix (data not shown). As empty vesicles 
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were expected to be less dense than BLP-DNA particles, an alternative method of 
purification employing a discontinuous sucrose gradient was adopted (Mok et al., 1999). 
Samples recovered after dialysis were loaded in a gradient of 2.5, 10 and 20% sucrose and 
centrifuged at 160.000 g for 5 h at 10 °C in swinging buckets. A control sample of 50 µg 
plasmid was centrifuged in identical conditions as used for BLP. The distribution of empty and 
DNA loaded BLP, as well as free DNA along the gradient was determined by DNA 
quantitation using the Sybr Green assay and size analysis by DLS. 
Figure 3.2 shows the relative amount of DNA recovered in each sucrose fraction, for free 
plasmid (panel A), and for three different lipid formulations of BLP-DNA (panels B-D). The free 
plasmid in control sample without BLP, concentrated in the 20% sucrose fraction. In the case 
of samples containing BLP-DNA, nearly 90% of the plasmid loaded on the gradient was 
recovered in the 10% sucrose fraction whereas less than 2% of the total DNA loaded was 
located in the 20% sucrose fraction.  
In order to correlate the presence of DNA with the presence of lipid particles, size 
measurements were carried out on each sucrose fraction by DLS (Left panel). The 2.5% 
sucrose fraction was enriched in particles with a mean size of ~60 nm, correlating with the 
size of empty BLP, whereas the 10% sucrose fraction contained particles larger than 200 nm, 
most likely corresponding to DNA loaded BLP.   
 
           A                    B            C                    D  
 
Figure 3.2: DNA distribution across the sucrose density gradient. A: control of free plasmid recovered 
in the 20% sucrose fraction. B: BLP-DNA formulated with 2.7% PEG-Cer-C8. C: BLP-DNA formulated with 
10% PEG-Cer-C8. D: BLP-DNA formulated with 2.7% PEG-DSGS. The left panel shows the size analysis by 
DLS. The 2.5% sucrose fractions containing less than the 5% of loaded DNA concentrated vesicles of 50-
60 nm in size, whereas the 10% sucrose fraction with 90% of the loaded DNA contained particles bigger 
than 200 nm. Total DNA was quantitated by Sybr Green assay after dissolution of BLP with 0.1% Triton X-
100 to release encapsulated DNA. Free plasmid amount in samples without BLP was also calculated in 
the presence of 0.1% Triton X-100.  
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These results demonstrated that ultracentrifugation in a sucrose densitiy gradient 
constitutes a useful and convenient technique for BLP-DNA purification. 
3.1.4.  Effect of PEG content in DNA encapsulation efficiency and particle size 
One objective of the characterization of BLP was to determine whether the PEG content 
in the formulation had a direct effect on BLP size, plasmid DNA encapsulation efficiency and 
plasmid DNA protection. 
DNA was considered to be encapsulated in BLP, if it was able to interact with Sybr Green 
only after solubilization of the lipid particles with 0.1% Triton X-100. Therefore, the DNA 
encapsulation efficiency in BLP samples recovered after detergent dialysis was estimated by 
measuring Sybr Green fluorescence before and after addition of 0.1% Triton X-100 and was 
defined as: 
 
 µg of DNA (+) Triton X100 - µg of DNA (-) Triton X100
DNA encapsulation efficiency (%) =
 µg of DNA added
x 100
 
 
For successful gene delivery and expression, the encapsulated plasmid DNA has to be 
protected from the extracellular environment. Therefore, DNA protection was measured in 
samples purified from sucrose density gradient by measuring Sybr Green fluorescence before 
and after addition of 0.1% Triton X-100 but, in this case, related to the total DNA recovered in 
the purified fraction: 
 
DNA protection (%) =
 µg of DNA (+) Triton X100 - µg of DNA (-) Triton X100 x 100
µg of DNA (+) Triton X100  
 
Encapsulation efficiency after the detergent dialysis and DNA protection after the sucrose 
gradient were compared among four formulations with differences in PEG content and PEG-
lipids composition and were related to the BLP size as determined by DLS.  
As shown in Table 3.2, neither the efficiency of encapsulation (40-70%) nor DNA protection 
(65-70%) were sensibly affected by the PEG percentage, PEG-lipids or initial plasmid 
concentration.  
The effect of different PEG content demonstrated a deeper impact in the final size than in 
the encapsulation efficiency of DNA in BLP. Only BLP formulated with 10% PEG-Cer-C20, 
formed particles of discrete sizes between 50 nm and 350 after detergent dialysis in line with 
previous observations on SPLP (Wheeler et al., 1999). 
After sucrose density gradient, BLP populations with discrete sizes between 70 nm and 340 
nm were resolved for all formulations except for BLP with 2.7% PEG-Cer-C8 that tended to 
form aggregates. This observation was expected and it could be attributed to the effect of 
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both, low PEG content and short acyl chain ceramide (C8) generating less sterically 
stabilized BLP than those containing 10% PEG-Cer-C20. 
 
 After detergent dialysis After sucrose density gradient 
% PEGylated lipid Size (nm) 
DNA 
encapsulation 
efficiency (%) 
 
Size (nm) DNA protection (%) 
10% PEG-Cer-C20 50-350 10, 66 70, 90, 160, 110, 340 72 
10% PEG-Cer-C8 50-1000 57 ± 4 80, 140, 160, 190, 220 64 
2.7% PEG-Cer-C8 50-1000 42 ± 10 > 500 nm 68 
2.7% PEG-DSGS 50-1000 62 ± 12 90, 150, 150, 220 66 
 
Table 3.2: Plasmid DNA encapsulation efficiency and protection in BLP. DNA encapsulation and 
protection were measured in samples recovered after dialysis and purified from sucrose density 
gradient, respectively. DNA was quantified using Sybr Green in the presence and absence of 0.1% 
Triton X-100. The differences in PEG content in the BLP formulations showed more impact in the final size 
of the particle than in the DNA encapsulation efficiency or protection in BLP. Data obtained from 3-5 
independent BLP preparations for each formulation. DNA encapsulation efficiency was expressed as 
average ± SD whereas DNA protection was expressed as median values. 
3.1.5.  BLP size analysis by AFM 
The morphology of the BLP-DNA was explored by Atomic Force Microscopy (Ruozi et al., 
2005). Droplets of constant volume of BLP were deposited on a mica surface and scanning 
was carried out in air using tapping mode. This operation mode was selected because the 
contact between the tip and the sample is minimized and therefore, is more suitable for the 
study of soft and deformable samples, such as liposomes. Sample tilt was removed by 
flattening the AFM image using second-order fitting. 
In Figure 3.3A, a 3-D topographical image of BLP-DNA formulated with 10% PEG-Cer-C20 
shows a population of spherical particles as expected for liposome based delivery systems 
(Lasic and Papahadjopoulos, 1995). Three lipid particles were selected from the top view of 
the image in Fig.3.3A and their diameter estimated along the line profiles shown in Figure 
3.3C, i.e. as the vertical distance between the mica surface and the top of the particles. Size 
values between 180-350 nm were obtained, in agreement with the mean hydrodynamic 
diameters calculated by DLS for this formulation (Table 3.2). The major drawback of this 
technique is the possible deformation of the soft liposomal sample due to solvent 
evaporation and the vertical force applied with the tip. 
 
 
3. Results: “Characterization of Biotinylated Lipid Particles” 
 51 
 
   
A 
 
B         C 
 
 
Figure 3.3: Representative AFM images of BLP-DNA on mica surface performed on tapping mode in 
air. A: 3-D topographical view from the height image. B: 2-D height image, top view from A. C: Height 
profiles along the lines shown in B. BLP-DNA with 10% PEG-Cer-C20 recovered from sucrose density 
gradient. 
 
3.1.6. Encapsulation of QDs in BLP by the detergent dialysis method 
BLP particles prepared by the detergent dialysis method were initially conceived for DNA 
encapsulation. However, to address the specificity of BLP binding to cells after tagging the 
particles with the EGF ligand, a fluorescent BLP was required. Therefore, the detergent dialysis 
technique was explored for the encapsulation of red emitting QD655 with a mean core size of 
10 nm in formulations containing 1.4 and 2.7% PEG-Cer-C8 and 1.4 % PEG-DSGS. 
During detergent dialysis of lipids-QD655 mixtures, the typical turbidity observed during BLP-
DNA formation was not noticeable. In order to determine whether QDs were indeed 
encapsulated in lipid particles, samples were loaded directly in the sucrose density gradient 
337 nm 
187 nm 
275 nm 
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using the same conditions as those employed for BLP-DNA and QDs fluorescence intensity 
distribution was examined under UV light excitation. 
3.1.7. Characterization of fluorescent BLP-QDs 
After ultracentrifugation in the sucrose gradient, three well-defined fluorescent fractions 
were observed (Figure 3.4A): a less dense bright fluorescent band on top (fraction I), a 
broader and less intense fluorescent band underneath (fraction II) and a fluorescent pellet 
(fraction III). The different densities of the particles concentrated in the two upper bands 
(fractions I and II) could be the result of a variable number of QDs encapsulated per particle. 
On the other hand, the pellet was enriched in free QDs and no biotin was detected in this 
fraction indicating the absence of lipid particles.  As the brightest band may also contain 
free lipids and empty vesicles, this fraction was not further characterized. 
Electron dense QD cores allow their detection by electron microscopy. TEM performed on 
particles recovered from fraction II (Figure 3.4B), revealed BLP containing on average of 2 to 
5 encapsulated QDs. The diameter of the BLP varied from 100 to 130 nm, depending on the 
number of loaded QDs.  Empty BLP or those containing only one QD were generally smaller 
than 100 nm. These values were in agreement with those obtained by DLS measurements for 
BLP-QD (Figure 3.4 C). The mean hydrodynamic diameter for BLP in fraction II, determined for 
two independent preparations and three different formulations was 109 ±16 nm (pdi <0.25). 
This fraction was recovered for coupling the EGF ligand to target the BLP to A431 cells. 
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Figure 3.4: Purification and size characterization of BLP-QD. A: Fluorescent fractions corresponding to 
particles associated with QDs were found on the top layers of the gradient (fractions I and II) whereas 
free QDs were found mainly in the pellet (fraction III). B: TEM image of BLP showing particles of 100-180 
nm in diameter containing 2-5 encapsulated QDs. Empty liposomes smaller than 100 nm. Scale bar 500 
nm. C: Representative size distribution of BLP formulations with encapsulated QDs measured by DLS 
after dialysis and after purification in sucrose density gradient.  
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In summary, the size analysis of BLP-DNA particles by DLS indicated that their final size 
could be modulated by varying the percentage of PEG content. For BLP-DNA, formulations 
containing 10% PEG-Cer-C20, 10% PEG-Cer-C8 or 2.7% PEG-DSGS showed that particles with 
a size ranging from 150 to 350 nm could be recovered from sucrose density gradients. 
In a novel application of the detergent dialysis technique, QDs were successfully 
encapsulated in BLP, showing a monomodal size distribution within a range of 100-130 nm. In 
contrast to BLP-DNA, BLP-QDs remained stabilized and did not aggregate even when PEG-
lipid content was < 2.7%. In addition, ultracentrifugation in sucrose density gradient allowed 
the purification of BLP-DNA and BLP-QDs particles from non-encapsulated material and 
empty vesicles.  
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The epidermal growth factor receptor (EGFR, erbB1, HER1) is overexpressed in a broad 
spectrum of malignant tumors and, as discussed in the introduction, represents an interesting 
target for delivery of therapeutic liposomes (Kullberg et al., 2005; Mamot et al., 2005). 
Biotinylated EGF ligand conjugated to streptavidin-coated QDs binds to EGFR leading to the 
receptor activation and internalization (Lidke et al., 2004; Lidke et al., 2005). The attachment 
of the fluorescent nanoparticle did not impair the binding capacity and biological functions 
of this growth factor (Lidke et al., 2007).  
The aim of the work presented in this chapter was to target the purified BLP carrying either 
DNA or QDs to A431 cells overexpressing the EGFR by tagging the particles with the EGF 
ligand. The first concern to be addressed, was whether the internalization of EGF tagged BLP 
could be impaired, as the large size of the lipid carrier may interfere with the dimerization of 
the EGFR necessary for the subsequent activation and internalization by endocytosis. 
The targeted delivery system was evaluated regarding: 
 binding ability 
 intracellular fate of targeted BLP 
 delivery of encapsulated QDs 
 transfection efficiency of the encapsulated DNA  
  The effect of PEG content and the presence of a pH sensitive lipid or PEG-ceramides with 
variable carbon-chain lengths in the efficiency of cargo delivery were investigated. 
The specificity for the EGFR was examined in a competitive binding assay in the presence 
of free EGF ligand. In addition, EGFR targeted BLP were incubated with two different cell lines 
that do not express the EGF receptor. 
Labeling and targeting of BLP were achieved by coupling preformed EGF-QD complexes 
providing a monitoring tool for the specificity of BLP uptake and cargo release in live cells by 
confocal laser scan microscopy (CLSM).  
4.1. Targeting and labeling of BLP 
In order to target the BLP to the EGFR, particles loaded with QD655 (red) were coupled via 
biotin-streptavidin linkage to preformed complexes of EGF-QD525 (green) as depicted in 
Figure 4.1. These particles were detected by CLSM in live cells, using a single excitation 
wavelength for both QDs colors. With this approach, colocalized red-green dots would be 
indicative of specific uptake, whereas red fluorescence would reveal unspecific binding of 
non-targeted BLP-QD655. Free unconjugated EGF-QD525 can be clearly distinguished as single 
green dots. 
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Figure 4.1: Scheme depicting the targeting and labeling strategy of BLP with encapsulated QD655. 
Preformed complexes of EGF-QD525, (molar ratio 4:1) were conjugated to biotin molecules on the BLP 
surface. Specific uptake would be evidenced as colocalized dots by confocal fluorescence 
microscopy. Red fluorescence would indicate unspecific binding of non-targeted BLP-QD655. Free 
unconjugated EGF-QD525, when present, would be detected as green dots.  
 
The strategy of adding the EGF ligand as a preformed complex with QDs instead of direct 
binding to BLP was adopted in order to take advantage of the multiple streptavidins coating 
the nanoparticle. The QDs used in this study carried 6-8 streptavidins (according to the 
manufacturer). Therefore, the amount of biotinylated EGF ligands per QD particle was 
selected to enhance binding while still leaving unoccupied streptavidins for coupling to BLP. 
The two-color BLP labeling strategy was designed to evaluate whether specific uptake of 
BLP and the cytoplasmic delivery of the cargo took place. Intracellular colocalization of both 
nanoparticles would indicate not only the specific uptake but the presence of QD655 still 
trapped inside the lipid particle and poor release. If the BLP were able to fuse with 
endosomal membranes and release the QDs, colocalization was expected be lost and the 
characteristic blinking of individual QDs be observed. 
4.1.1.  Cell uptake of targeted BLP-QDs  
The interaction of BLP with A431 cells was evaluated by fluorescence confocal 
microscopy with EGF-tagged and dual-labeled BLP containing 1.4% and 2.7% PEG-Cer-C8 
and 1.4% PEG-DSGS upon incubation for 1 h at 37 °C. As shown in Figure 4.2, both QDs 
extensively colocalized after 1 h, indicating that targeted EGF-QD525-BLP-QD655 particles were 
internalized. Non-targeted BLP-QD655 were not taken up by cells or were observed as a faint 
fluorescence for all lipid formulations examined (Figure 4.2 panels A, B, C). The cell uptake of 
BLP was associated with a dot-pattern distribution, which could be attributed to the 
clustering of the lipid particles in endosomal compartments.  
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Figure 4.2: Intracellular localization of targeted EGF-QD525-BLP-QD655 and non-targeted BLP-QD655 . 
A431 cells were incubated with EGFR targeted and non-targeted BLP for 1 h at 37 °C. Unbound 
complexes were removed and live imaging performed by confocal fluorescence microscopy at RT in 
Tyrode’s buffer. A: BLP-QDs 1.4% PEG-Cer-C8. B: BLP-QDs 2.7% PEG-Cer-C8. C: BLP-QDs 1.4% PEG-DSGS. 
Colocalization of QD525 and QD655 showing BLP distributed in presumably endosomal compartments. 
Scale bar: 10 µm. 
 
4.1.2. Intracellular distribution of internalized BLP 
Figure 4.3 (Panels A-C) shows a reconstructed three-dimensional image of two A431 cells 
that had internalized many targeted BLP-QDs during a 10 min pulse followed by 1h 
incubation (chase) at 37 °C. Interestingly, most of the internalized EGF-QD525-BLP-QD655 
complexes accumulated in the perinuclear region of the cell (Panel A), although a large 
fraction was still visible in small structures underneath the cell membrane (Panel B). Close 
observation of single vesicles inside the cells (Panel D) showed that colocalized QDs had 
variable intensities for each QD color as evidenced by the heterogenous yellow-orange 
pseudocolor. This could be explained as a distribution in the number of encapsulated QDs in 
BLP (1-5 QDs) as showed by TEM (Fig. 3.4), and presumably the presence of a variable 
number of EGF-QD525 bound per lipid particle. In addition, and possibly most important, fusion 
of vesicles ocurring during endosomal sorting (Maxfield and Yamashiro, 1987) could have 
brought several particles together.  
Single green dots (Figure 4.3D and E) indicating free EGF-QD525, were expected, as they 
were not eliminated from the initial incubation mixture with BLP. 
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Figure 4.3: Intracellular fate of EGFR targeted and QDs labeled BLP. A: 3-D reconstruction of two A431 
cells with internalized BLP after 10 min pulse incubation and 1 h chase at 37 °C. B: y-z plane showing 
colocalized QDs inside cells and underneath the cell membrane. C: Overlay of image A with DIC 
image. D: Line-profile across endosomal vesicles. E: Fluorescence intensity along the line-profile in D 
revealing different intensity levels for colocalized QDs as well as size variations among vesicles. 
Internalized two-color QDs labeled and targeted BLP were distinguished from independently 
internalized green EGF-QD525 complexes (arrowheads in panels D and E). Scale bar 2 µm. 
4.1.3. Time course of  BLP internalization 
Quantitative binding and endocytosis analysis of preformed complexes of EGF-QDs in 
A431 cells has shown that ~50% of the QD ligands accumulated intracellularly in 
approximately 20 min (Lidke et al., 2004). To get insight into the time course of binding and 
endocytosis of BLP tagged with preformed EGF-QD525 complexes, confocal microscopy was 
performed on live A431 cells for 1 h in the presence of the targeted particles. Figure 4.4 shows 
that visible accumulation of dual-labeled and targeted BLP on the cell membrane occurred 
during the first 10 min of incubation. After 20 min, targeted BLP were identified as colocalized 
yellow dots internalized and close to the cell membrane in a pattern similar to that described 
for single EGF-QDs.  
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Figure 4.4: Real time uptake of targeted BLP in A431 cells. Targeted BLP were present during the 
acquisition of confocal images. After 10 min BLP were already bound to the cell membrane and small 
dots were distinguished. After 20 min, an increase in fluorescence intensity indicated a clustering of the 
particles. The size of vesicles increased during the process, probably as the result of vesicles fusion. After 
1 h, particles were still binding to the cell membrane. Final concentrations in the binding reaction: 4 nM 
EGF, 1 nM QD525. Scale bar 10 µm. 
 
This result suggests that the size of the BLP did not delay the uptake mediated by EGF. 
After 60 min a shift of the colocalized dots toward the perinuclear region was accompanied 
with a clustering of fused endosomal vesicles as evidenced by the increasing fluorescent 
intensity. These observations are in agreement with those reported for ligand induced 
activation of the EGFR by preformed complexes of EGF-QDs (Lidke et al., 2004). 
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4.1.4. EGFR targeted BLP follow the route of EGF-QDs complexes 
In order to determine whether the targeted BLP followed the same route as EGF-QDs 
complexes and indeed were sorted from early endosomes, the uptake of EGF tagged BLP 
was compared to that of free EGF-QDs complexes and labeled ligand Transferrin. Although 
the endocytosis of EGFR and Transferrin receptor share the same clathrin-dependent 
pathway in A431 cells, they are differentially sorted from early endosomes (Hanover et al., 
1984; Lamaze et al., 1993). Whereas Transferrin receptor is constitutively recycled back to the 
cell membrane, EGFR internalization is ligand-induced and EGF-EGFR complexes are mainly 
sorted to mature lysosomes as a general downregulation mechanism for growth factors 
receptors (Hanover et al., 1984) (Hopkins et al., 1985). Therefore, binding and uptake of 
targeted BLP were examined in the presence of Transferrin-Alexa488 (TA) after 10, 30 and 120 
min incubation with A431 cells (Figure 4.5). 
EGF-QD605-BLP-QD655 and TA were added simultaneously to cells and incubated for 15 min 
at 4 °C to allow binding while avoiding endocytosis, followed by 10 min or 30 min incubation 
at 37 °C. Cells were rinsed to remove the unbound complexes and were fixed immediately 
for confocal microscopy analysis. In a second experiment, cells were incubated with EGF-
QD605-BLP-QD655 for 120 min at 37 °C and TA was added for 10 min before removing the 
unbound complexes.  
As shown in Figure 4.5A, after 10 min of incubation EGF-QD605-BLP-QD655 extensively 
colocalized with TA at the cell membrane [r= 0.59]. After 30 min, targeted BLP partially 
colocalized with Transferrin [r= 0.37] and colocalization completely disappeared after 120 
min [r= 0.14]. At this time, targeted BLP clustered around the perinuclear zone were likely 
sorted from early endosomes.  
Control samples of EGF-QD605 and TA simultaneously incubated with A431 cells for 30 min 
at 37 °C (Figure 4.5B), still showed partial colocalization of both ligands [r= 0.5] but barely 
colocalized after 2 h [r= 0.3]. 
 
Figure 4.5 A: Sorting pathway of EGF-QD605-BLP-QD655 in A431 cells: Targeted BLP and TA added 
simultaneously extensively colocalized at the cell membrane after 10 min (r=0.59) and partially 
colocalized after 30 min (r=0.37). After 120 min targeted BLP appeared in clusters around the 
perinuclear region and no colocalization with TA was observed (r=0.14). Triple-color colocalization of 
QD605, QD655 and TA is highlighted in white. 
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Figure 4.5 B: Control experiments without BLP. EGF-QD605 and TA added simultaneously and 
incubated for 30 min showed partial colocalization (r= 0.51) and after 2 h, they were partially 
colocalized (r= 0.3). Correlation plots on the right show the corresponding Pearson’s coefficients (r). 
Confocal images were acquired in fixed cells. BLP formulations: 2.7% PEG-Cer-C8, 1.4 % PEG-DSGS and 
0.5 nM EGF, 2 nM QD605. Scale bars 10 µm.   
 
These observations support the idea that EGF tagged BLP followed the route of free EGF 
mediated endocytosis, sorting out from early endosomes after 20-30 min diverging from 
Transferrin ligand in the internalization pathway. 
4.1.5.  Intracellular fate of QDs encapsulated in targeted BLP 
It is well described that trafficking from early to late endosomes in clathrin mediated 
endocytosis takes place within 20 min (Vonderheit and Helenius, 2005). According to the 
results observed with Transferrin, if targeted BLP were sorted from early endosomes after 30 
min, BLP bearing pH sensitive or exchangeable lipids would be in principle able to fuse more 
readily with the endosomal membranes, thereby releasing the QDs. Therefore, for the dual-
labeled EGF-QD525-BLP-QD655 complexes, the initial colocalization observed within 30 min was 
expected to decrease with time. 
Targeted and non-targeted BLP-QD655 were incubated with cells for 10 min (pulse) at 37 
°C, unbound complexes were washed  and the QD labels chased for 4 h (Figure 4.6A) and 
12 h (Figure 4.6B). Even after after 12 h, dissociation of the two QD signals was not apparent, 
indicating that the encapsulated QDs were not able to escape from the endosomes. 
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Figure 4.6: Fate of encapsulated QD655 delivered by EGF-QD525-BLP-QD655. After 10 min of incubation 
at 37 °C with A431 cells, unbound EGF-QD525-BLPQD655 were removed and cells imaged for up to 12 h. 
Colocalization of EGF-QD525 tagged BLP with encapsulated QD655 was visualized on live cells by 
confocal microscopy.  Both QDs remained extensively colocalized after 4 h (A) and after 12 h (B), 
showing no evidence of QDs release in the cytoplasm. C: Non-targeted BLP-QD655.  Scale bar 10 µm. 
 
4.2.  Receptor specificity of targeted BLP   
4.2.1. Competitive assay 
To evaluate whether the EGFR was involved in the endocytic uptake of targeted BLP, a 
competition assay was carried out by adding the EGF-QD525-BLP-QD655 complexes to A431 
cells in the presence of a 66-fold molar excess of free ligand EGF. Under these conditions, the 
binding of the targeted BLP was substantially diminished (Figure 4.7B), as compared to the 
positive controls in absence of free ligand (Figure 4.7A). 
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4.2.2. Interaction of BLP with EGFR-negative cells 
In order to confirm that the EGFR was essential for the improved uptake, additional 
experiments with EGFR-negative cells were performed. Neither CHO cells nor WM983A cells 
internalized the EGFR targeted BLP as observed in Figure 4.7C and D. 
 
 
 
Figure 4.7: Binding specificity of targeted BLP for EGFR. A: A431 cells incubated with EGF-QD605-BLP-
QD655. B: Cells coincubated with EGF-QD605-BLP-QD655 and a 66-fold molar excess of free competing 
ligand EGF. C: CHO cells devoid of EGFR incubated with targeted BLP. D: WM983A cells devoid of EGFR 
incubated with targeted BLP. Scale bar 10 µm. 
 
Taken together, these results indicated that the enhanced uptake of targeted BLP was 
due to the specific interaction with EGFR.  
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4.3. Delivery and transfection abilities of targeted and QDs labeled BLP-DNA 
The results obtained with BLP loaded with QDs indicated that although receptor- 
mediated uptake was taking place, the release of QDs from endosomal compartments was 
not Demonstrated. Additionally, because encapsulated QDs are coated with carboxyl 
groups could be speculated that they are neutralized in the acidic environment of 
endosomes forming aggregates before being released. Therefore, the delivery ability was 
further explored with EGFR targeted BLP carrying encapsulated DNA containing the GFP as 
reporter gene. The efficiency of the targeted gene delivery was estimated as the 
percentage of GFP positive cells, compared to that obtained with the non-targeted BLP.  
4.3.1.  Intracellular fate of dual-labeled and targeted BLP-DNA 
In order to monitor the initial binding and uptake of BLP with encapsulated DNA, these 
particles were also labeled with two colors of QDs with a modified strategy as depicted in 
Figure 4.8. In order to assess the specificity of binding and track the particles, BLP-DNA were 
first coupled to preformed EGF-QD525 complexes, followed by a second color labeling using 
QD655 without EGF.  
Targeted particles are denoted as (EGF-QD525/QD655)-BLP-DNA. As free QD655 does not 
internalize in the absence of ligand, the uptake of QD655 is dependent on previous binding to 
targeted EGF-QD525-BLP-DNA. Similar to the BLP-QDs labeling strategy, colocalized QD525 and 
QD655 in this case would be indicative of the presence of EGF targeted particles. The 
monocolor non-targeted particles labeled with QD655   are denoted as (QD655)-BLP-DNA.  
 
 
Figure 4.8: Diagram depicting the targeting and labeling strategy of BLP with encapsulated DNA. 
Preformed complexes of EGF-QD525, containing 2-4 EGF molecules per QD particle, were conjugated to 
biotins on BLP. In a subsequent step, the second color QD655 was added at equimolar amounts as 
QD525. Specific uptake would be evidenced as colocalized dots, while unspecific uptake as red 
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fluorescence of non-targeted BLP-DNA labeled only with QD655. BLP formulations employed: 10% PEG-
Cer-C20, 10 % PEG-Cer-C8 and 2.7 % PEG-DSGS.  
 
The binding was performed as already described for BLP-QDs. For BLP-DNA formulations, 
PEG content was increased to 10% of PEG-Cer-C8 and C20. 
 First, (EGF-QD525/QD655)-BLP-DNA were prepared with 10% PEG-Cer-C20. This formulation 
showed an average size of 70 nm, DNA encapsulation efficiency of <50% and was the 
targeted analogue of described SPLP (Wheeler et al., 1999). Due to their homegeneous and 
small size compared to the other formulations tested, they were examined for binding and 
targeting ability in A431 cells. Upon incubation with cells for 3 h at 37 °C unbound complexes 
were removed and uptake was analyzed in live cells by confocal fluorescence microscopy.  
As shown in Figure 4.9A, targeted (EGF-QD525/QD655)-BLP-DNA were identified as 
colocalized QD525 and QD655, (yellow pseudocolor in the overlay). The distribution in a dot 
pattern was consistent with endosomal localization, as previously observed for QDs loaded 
BLP. No uptake was detected for the non-targeted BLP for the same incubation conditions 
(Figure 4.9B). Control experiments with EGF-QD525 and free QD655 showed that non-targeted 
QD655 were not internalized (Figure 4.9B).  
 
 
 
Figure 4.9: Binding and uptake of EGF-QD525-QD655 BLP-DNA. A: A431 cells were incubated with 
targeted particles for 3 h at 37 °C. Live imaging performed in Tyrode’s buffer with 1% glucose. The dot 
pattern suggested endosomal localization. B: Control experiments with QD655 (left panels) and EGF-
QD525, showing that non-targeted particles were not internalized. BLP formulation: 10% PEG-Cer-C20. 
Scale bar 10 µm. 
 
These results indicated that binding was not impaired for targeted BLP-DNA despite the 
high PEG content (10%PEG-Cer-C20).  
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4.3.2. Transfection competency of dual-labeled and targeted BLP-DNA 
The transfection activity of dual-labeled and targeted BLP-DNA was explored in 
formulations containing lower PEG content (2.7%) and pH sensitive lipids. Starved A431 cells 
were incubated with (EGF-QD605/QD655)-BLP-DNA for 10 min at 37 °C cells, then unbound 
complexes were removed and BLP distribution and GFP expression in A431 cells were 
analyzed after 48 h. 
Figure 4.10 (A,B), demonstrates that EGFR-targeted BLP loaded with DNA behaved 
similarly to BLP-QDs regarding the binding and cellular distribution upon internalization of the 
particles. The presence of colocalized dots in non-transfected cells (Figure 4.10A), may 
reflect a difficulty of BLP to destabilize the endosomes or, alternatively, may indicate the 
presence of targeted but empty particles, as expected for the 70% DNA encapsulation 
efficiency obtained. In Figure 4.10C a 3D-reconstruction of confocal planes shows the 
perinuclear localization of targeted BLP in cells expressing GFP. 
 
 
Figure 4.10: GFP expression upon plasmid delivery with dual-labeled and EGFR targeted BLP-DNA. 
(EGF-QD525/QD655)-BLP-DNA were incubated for 10 min at 37 °C in Tyrode’s buffer ph 7.4, then unbound 
complexes were removed and cells were incubated in complete DMEM for 48 h before imaging. A: 
Merged images corresponding to colocalized QDs (overlay of QD605/655 channels) with the green 
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channel corresponding to GFP fluorescence (pseudo color, white). B: Image on A merged with the DIC 
image. C: Three-dimensional reconstruction. The x-y section, as indicated by the blue lines in the x-z and 
y-z projections, showed the internalized BLP. BLP formulation: 2.7% PEG DSGS, 1μg plasmid /well, BLP-
DNA particle size ~200 nm. Scale bar 10 µm. 
 
The two-color BLP labeling strategy allowed to associate the presence of internalized 
targeted particles with their transfection ability as indicated by the expression of GFP. 
4.3.3. BLP targeting in a two-step procedure 
In order to improve the access of EGF to the cell surface and decrease the formation of 
possible crosslinked species, the coupling of preformed complexes of EGF-QDs to BLP was 
performed in two steps. The advantage of using this procedure has been also described by 
(Lidke et al., 2007). 
In a first step, to accomplish the targeted delivery, preformed complexes of EGF-QDs 
were added to target A431 cells at 4 °C to prevent early internalization. In a second step, 
BLP-DNA samples recovered after detergent dialysis (non-purified fractions) or purified in 
sucrose gradient (purified fractions) were added to the cells at 10 °C for 15 min and then 
incubated at 37 °C during 30 or 60 min before removing the BLP. A431 cells incubated 
directly with non-purified and purified fractions BLP-DNA (only Step 2) were employed as 
control of non-targeted delivery.  
The percentage of transfected cells were quantified after 48 h by FACS or fluorescence 
microscopy. Although a smaller number of cells were evaluated by microscopy as 
compared to flow cytometry, the sensitivity for fluorescence detection was improved using a 
CCD camera to allow the detection of the onset of GFP expression at later times (Figure 
4.11A,B, red arrows).  
 
 
 
A                    B 
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Figure 4.11: GFP expression analysis in A431cells by a two-step targeting procedure. A: Control cells 
incubated with unmodified BLP-DNA (non-targeted delivery). B: Cells preincubated with EGF-QD655 
complexes followed by the addition of BLP-DNA (targeted delivery). After 48 h A431 cells with late onset 
of GFP expression, indicated by low levels of GFP were also detected. Green fluorescence: GFP positive 
cells. Blue fluorescence: Nuclear staining with Hoechst. 
 
As described in the previous chapter, fractions recovered after detergent dialysis and 
after sucrose densitiy gradient differ in the size homegeneity of the BLP particles, which can 
affect directly the binding, internalization efficiency and consequently the transfection ability 
of the targeted BLP. Therefore, it was of interest to evaluate the effect of non-purified and 
purified BLP-DNA fractions in the transfection efficiency of targeted particles containing 1 
and 2 µg plasmid DNA in each well. The percentage of cells expressing GFP following the 
two-step incubation procedure was determined by fluorescence microscopy and flow 
cytometry (Table 4.1). 
 
GFP expressing cells 
(%) by flow cytometry 
GFP expressing cells 
(%) by microscopy 
BLP Fraction and size range 
(-) EGF (+) EGF (-) EGF (+) EGF 
Non-purified   
50-1000 nm 3 3.9   
10% PEG-Cer-C8 
Purified        
80-220 nm 1.4 4.8 0 2.4 
Non-purified   
50-1000 nm 2.9 3.2   
2.7% PEG PEG-DSGS 
Purified        
90-220 nm 1.4 3.9 0.8 1.9 
 
Table 4.1: GFP expression levels obtained with purified and non-purified BLP-DNA. Samples 
recovered after detergent dialysis (Non-purified) and after sucrose density gradient (Purified) for two 
BLP formulations. Preformed complexes of EGF-QDs (2-4 nM EGF) were added to starved A431 cells at 
10 °C. Then, cells were incubated with BLP-DNA (1 or 2 µg plasmid) for 30 min at 37 °C (for flow 
cytometry measurements) or 60 min at 37 °C (for quantitative fluorescence microscopy). Non-purified 
fractions: Fractions of BLP recovered after detergent dialysis composed of non encapsulated plasmid 
(~40%), empty BLP and aggregates. Purified fractions: Fractions of BLP recovered after sucrose density 
gradient composed of BLP with encapsulated DNA. Values are median of 3-5 measurements with each 
method performed in three independent experiments. 
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As shown in Table 4.1 treatment with non-purified fractions (containing free plasmid and 
aggregates) produced similar number of GFP expressing cells for targeted and non-targeted 
delivery of BLP-DNA (3-4 %), indicating that non-targeted particles were equally efficient for 
transfection as targeted particles. Since equal amounts of free plasmid added did not show 
any transfection activity, the GFP expression observed for non-purified fractions was 
attributed to DNA-loaded BLP and aggregates of lipid-DNA, the later presumably entering 
through a non-receptor mediated route. 
When purified fractions were tested, targeted BLP-DNA showed 2-3-fold increase in GFP 
expression as compared to the non-targeted particles for both formulations analysed. 
Despite the very low total transfection efficiency of the BLP, this finding suggested that after 
removing the aggregates the transfection levels observed were presumably accomplished 
by smaller and targeted BLP-DNA (< 250 nm).  
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In the previous chapter, BLP tagged with QDs were used to monitor the specificity of the 
binding and receptor-mediated uptake of the carriers by fluorescence microscopy. The 
transfection efficiency of the targeted BLP-DNA was assessed by measuring the number  of 
GFP expressing cells. However, the intracellular localization of the plasmid at any time during 
the delivery process could not be determined and related to the fate of the BLP. At this 
point, the use of a fluorescently labeled plasmid is critical to shed light on the mechanism by 
which DNA is released from the lipid carrier. Coupling multiple fluorescent tags may involve 
covalent modifications of the plasmid DNA, which may interfere with the expression of the 
reporter gene. In this regard, the present chapter deals with the labeling of plasmids 
mediated by peptide nucleic acids (PNA) for non-covalent and sequence specific binding 
of a single QD to plasmid DNA. 
5.1. bis-PNA strand invasion of supercoiled plasmids  
The ability of bis-PNAs to form (PNA)2–DNA triplexes has been used for effective strand 
invasion of linear DNA duplexes, where the two bis-PNA strands are designed as a single 
molecule connected by flexible linkers (Cherny et al., 1998). Figure 5.1 depicts such a 
strategy, where bis-PNA, in this work modified with a single biotin, binds by Hoogsteen 
interactions to a unique target site in the pEGFP-C1 plasmid. The binding site in the plasmid is 
located far away from the transcription initiation site, in order to avoid any interference with 
the expression of the GFP reporter gene. One disadvantage of this strategy is that bis-PNAs 
are restricted to bind purine sequences due to steric hindrance of the Hoogsteen binding 
with target sites containing pyrimidine bases (Demidov et al., 2001). Therefore, hybridization 
takes place only under acidic conditions (~pH 5) to maintain the citosines protonated for 
Hydrogen-bond formation. 
 
Figure 5.1: Schemematic representation of hybridization of biotin-bis-PNA to a specific sequence in 
plasmid pEGFP-C1. 
 
In the strategy applied a biotynilated bis-PNA was employed for subsequent conjugation 
to streptavidin coated QDs (StAv-QDs).  
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Hybrids were prepared at 2:1, 4:1, 8:1, 20:1 and 40:1 biotin-bis-PNA to plasmid molar ratios 
and digested with the restriction enzymes Apa LI and Ase I to generate a short 379 bp DNA 
fragment containing the bis-PNA binding site and an additional 4352 bp fragment. 
Fragments were electrophoresed in a 3-8% gradient native polyacrylamide gel. The binding 
of biotin-bis-PNA is expected to retard the migration of the 379 bp fragment. As shown in 
Figure 5.2A, the Sybr Green stained gel revealed a retarded DNA band running behind the 
fragment containing the target sequence for biotin-bis-PNA. The amount of the retarded 
fragment notably increased at higher biotin-bis-PNA to plasmid molar ratio (20:1). In spite of 
the excess of biotin-bis-PNAs, less than 50 % Hybrid yield was estimated from the Sybr Green 
intensity of the retarded band. As the remaining larger restriction fragment (4352 bp) did not 
migrate in the gel due to the high percentage of polyacrylamide, a non-specific interaction 
between biotin-bis-PNA and this fragment could not be assessed. To address this problem, 
additional hybridization experiments were performed using a fluorescently labeled Cy5-bis-
PNA that could be detected independently of the size of the fragments. Similarly as before, 
hybrids were formed at Cy5-bis-PNA to plasmid molar ratios of 2:1, 4:1, 8:1, 20:1 and 40:1. In 
this case, the pEGFP-C1 plasmid was digested with Apa LI and Ava II to obtain DNA 
fragments of 2002 bp, 1641 bp (containing the target site), 445 bp and 643 bp. Hybrids were 
analyzed in a 2% agarose gel in 1X TAE and Cy5 fluorescence was detected before staining 
with Sybr Green. The left panel in Figure 5.2B shows a single band Cy5-labeled corresponding 
to the fragment of 1641 bp bearing the bis-PNA binding site. Cy5 fluorescence was not 
detected in the remaining restriction fragments, shown in the right panel of Figure 5.2B, 
representing the total DNA, as determined by Sybr Green stainning. These results indicated 
that unspecific hybridization is not taking place in the presence of 40-fold excess of bis-PNA 
to plamid DNA. 
 
  
 
5. Results: “Single Quantum Dot labeling of plasmid DNA” 
 77 
Figure 5.2: Hybrid formation between bis-PNA and pEGFP-C1 plasmid by restriction fragment 
analysis in gel electrophoresis. A: Retarded band migration in polyacrylamide gel 3-8 % in 1X TAE.  Sybr 
Green stained gel showing digested fragments obtained with Apa LI and Ase I. The 379 bp fragment 
contains the target sequence B: Restriction fragments obtained with Apa LI and Ava II and analyzed in 
2% agarose gel in 1X TAE. Left panel, Cy5 labeling; right panel, Sybr Green stainning. The 1641 bp 
fragment contains the PNA target sequence.  Biotin-bis-PNA (or Cy5-bis-PNA):plasmid molar ratios were 
2:1, 4:1, 8:1, 20:1, and 40:1. 
5.2. Quantum Dot labeling of biotin-bis-PNA: plasmid DNA Hybrids 
QD-Hybrid complexes (Figure 5.3) were formed by adding streptavidin coated QD655 to 
biotinylated Hybrids at 1:1 molar ratio.  
 
 
 
Figure 5.3: Diagram of a single StAv-QD-labeled plasmid mediated by biotin-bis-PNA hybridization 
 
The resulting mixture was analyzed by agarose gel electrophoresis along with control 
samples consisting of QDs alone or in the presence of plasmid. QD-Hybrids were scanned 
under UV light and the emission of QD655 was collected using a LP 580 filter. In addition, the 
gel was stained with Sybr Green to visualize total DNA (Figure 5.4). The band shift observed 
was the result of binding StAv-QDs to biotinylated Hybrids. This retarded migration was 
expected considering that QDs are slightly negative as compared to plasmid DNA and ran 
behind the plasmid when loaded alone (third lane). Furthermore, the StAvQD655 retarded the 
migration of both, supercoiled and the open-relaxed circular conformations of the plasmid, 
as evidenced by comparing QD labeled bands with Sybr Green stained bands (right panel). 
This also implied that Hybrids were stable in both conformations. The presence of faint 
retarded bands (red arrows) could be due to the binding of multiple biotin-bis-PNA:plasmid 
to a single QD, since the nanoparticles are coated by 6-8  streptavidins. This observation may 
also explain the presence of free StAv-QDs, although the reaction was carried out at 
equimolar amounts of QD particles and Hybrids. Controls of unbound QDs and plasmid DNA 
ran as the corresponding free molecules confirming the absence of non-specific interaction. 
As expected, DNA staining showed that hybridization was not complete, in good agreement 
with previous results obtained with restriction enzymes (Figure 5.2).  
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Attemps to purify the QD-labeled Hybrids by electroelution resulted in a very low sample 
recovery. 
 
Figure 5.4: Visualization of QD-labeled Hybrids. Gel electrophoresis performed in 0.8% agarose gel in 
1X TAE. Left panel, QD655 fluorescence. Right panel, Sybr green staining. StAv-QD655 to biotinylated 
Hybrids molar ratio was 1:1. 
5.2.1. Specificity of single QD labeling revealed by AFM  
Taking advantage of the rough and size of QD particles, direct visualization of the degree 
of labeling, as well as the specificity of bis-PNA for its target sequence was accomplished by 
AFM measurements.  
QD-Hybrids and the corresponding control plasmids were deposited on a mica surface in 
5 mM Mg+2 and imaged in tapping mode in air. Figure 5.5A displays representative amplitude 
images of supercoiled (top) and linear Hybrids (bottom). It is clearly visible from these images 
that a single QD was attached per DNA molecule, for both supercoiled and linear 
conformation of the plasmid. 
As a direct control for the specificity of the biotin-bis-PNA recognition, the position of the 
QDs was estimated in linearized Hybrids (Figure 5.5B, top panels). The length of the short 
protruding fragment measured from the center of the QD particle (segment between blue 
crosses) was estimated in ~63 nm (5.5B, bottom panel). Considering that the length of one 
base pair in the B-form of DNA is 0.34 nm, the protruding fragment would be ∼185 bp. This 
was considered a good approximation to the 208 bp-distance measured from the end of the 
target site (position 4523 bp) to the end of the fragment at position 4731 bp in pEGFP-C1. 
Thus, the experimentally determined binding location correlated well with the expected 
binding domain of bis-PNA. 
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Figure 5.5: Site specific QD labeling of Hybrids as revealed by AFM. A: Amplitud images of QD:Hybrid 
complexes showing a single QD attached per DNA molecule. B: Procedure applied to estimate the 
location of the bis-PNA binding site from the height images. The right image is a zoomed view of the 
box selected in the left image. The distance measured from the center of the QD particle to the end of 
the restriction fragment (double-headed arrow in the bottom panel) suggested that QD is positioned at 
the expected PNA binding site. 
 
In summary, AFM images clearly showed that a single QD was located at the target 
position in the Hybrid. This fact highlights the specificity of bis-PNA for its target sequence, as 
already demonstrated by gel electrophoresis.  
5.2.2.  Visualization of Hybrids and QD:Hybrids complexes on magnetic beads  
In order to explore whether QD labeling was suitable for tracking plasmids by 
fluorescence microscopy, QD:Hybrid complexes were coupled to magnetic beads. This 
approach was intended to imitate the conditions required for live cell imaging.  
Biotinylated Hybrids and QD-Hybrids were coupled to streptavidin or biotin coated 
magnetic beads, respectively. After incubation, beads were washed to remove unbound 
material and were stained with Sybr Green to reveal attached plasmid DNA. The samples 
were deposited on glass coverslips and Sybr Green and QD655 fluorescence were then 
visualized in a wide field inverted microscope equipped with a CCD camera. The results are 
summarized in Figure 5.6. In a first set of experiments, biotinylated Hybrids were incubated 
with streptavidin-coated magnetic beads. This preparation showed positive DNA staining 
revealing the presence of Hybrids (Figure 5.6A). Neither Syber Green nor StAv-QD655 signal 
were detected in control experiments performed with unmodified plasmid (Figure 5.6B). 
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In a second set of experiments, the QD-Hybrid complexes were incubated with biotin-
coated magnetic beads and then DNA was stained with Sybr Green. In this case, 
colocalization of Sybr Green and QD655 fluorescence was observed only when the StAv-QDs 
were preincubated with the biotinylated Hybrid before the addition to the beads (Figure 
5.6C). As expected, StAv-QDs were also bound to biotinylated magnetic beads (Figure 5.6D).  
 
 
 
Figure 5.6: Visualization of QD labeled Hybrids coupled to magnetic beads by fluorescence 
microscopy. A: Biotinylated Hybrids incubated with streptavidin-coated magnetic beads. B: Control of 
unmodified pEGFP-C1 plasmid incubated with streptavidin-coated magnetic beads.  C: QD-Hybrids 
incubated with biotin-coated magnetic beads. 20 nM biotinylated Hybrids were preincubated with 
StAv QD655 (2 nM QDs) in Sodium Borate buffer pH 8.5 before addition to the magnetic beads. D: StAv-
QD655 incubated with biotin-coated magnetic beads.  Ex/Em filters: for Sybr Green: ex. 480/30 BP, 505 
DM (dichroic mirror), em. 535/40 BP, QD655 ex. 560/55 BP, 595 DM , em. 655/40 BP. 
 
In summary, although Hybrids yield and purification of labeled complexes need further 
optimization, the results presented in this chapter point out the potential of peptide nucleic 
acids as useful tools for the site specific non-covalent labeling of plasmids. In addition, the 
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sensitivity provided by the highly fluorescent and photostable QDs would allow single 
molecule tracking of the Hybrids in live cells by fluorescence microscopy. 
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The new era of PEGylated liposomes has greatly improved the systemic delivery of 
therapeutic agents into tumor or disease-affected tissues in distal locations of the body 
(Woodle and Lasic, 1992; Harris and Chess, 2003). To introduce cell specificity receptor-
mediated endocytic pathways are being exploited for nonviral gene/drug delivery. For this 
purpose, targeting molecules have been incorporated into liposomal carriers. For instance, 
coupling of suitable ligands and antibodies to these synthetic vehicles, particularly to target 
cell receptors overexpressed in certain tumors, has enhanced enormously the specificity of 
delivery, reducing toxic side effects in normal surrounding tissues (Hofland et al., 2002; Wei et 
al., 2003).  
Stabilized Plasmid Lipid Particles (SPLP) are a new generation of liposomes, stabilized by 
PEG-Ceramide lipids. SPLP are able to encapsulate plasmid DNA with high efficiency (50-
70%) in particles smaller than 100 nm (Fenske et al., 2002). An unwanted side effect of PEG-
Ceramide coating on SPLP, necessary to engender the long circulation lifetimes, is the 
putative inhibition of liposome-cell association and uptake required for an efficient 
transfection. Therefore, the dissociation rate of PEG-Ceramides from SPLP has been 
modulated by varying the acyl chain length of the ceramide anchor. The transfection 
efficiency of these particles have proven superior after replacing PEG-Cer-C20 by a shorter 
acyl chain PEG-Cer-C8 (Mok et al., 1999). 
An essential improvement can be expected from the inclusion of cell-specific targeting 
ligands on SPLP. However, this possibility had not been explored prior to this thesis. A single 
application was recently reported for lactoferrin tagged SPLP aimed to specifically transfect 
hepatocytes in vivo (Weeke-Klimp et al., 2007). This approach, despite showing efficient cell 
targeting and transfection capacity in vitro, was unable to accomplish the expression of the 
reporter gene in vivo. 
The epidermal growth factor receptor (EGFR, erbB1, HER1) is an attractive target for drug 
and gene delivery since it is overexpressed in a wide variety of human tumors, including lung, 
liver and breast cancer (Yarden, 2001). Deep knowledge into the dynamics of EGF-EGFR 
interactions has been achieved with the application of targeted Quantum Dots (QDs). 
Fluorescent QDs conjugated with EGF ligand have enabled the recognition of multiple 
targets and elucidation of cellular dynamic processes such as activation and signal 
transduction mediated by the receptor tyrosin kinase erbB1 (Lidke et al., 2004) as well as a  
mechanism of retrograde transport in filopodia (Lidke et al., 2005). Their exceptional 
photostability is the essential feature for long-term fluorescence imaging (Smith et al., 2004). 
Prior to this thesis, the application of EGF tagged QD for targeting and labeling of SPLP-like 
carriers had not been explored. Therefore, a combined strategy of EGFR targeting and QD 
labeling was developed for modified SPLP. Biotinylated and stabilized lipid particles (BLP) 
were loaded with plasmid DNA or QDs and modified with preformed complexes of EGF-QDs 
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in order to accomplish targeted delivery into A431cells overexpressing the EGF receptor 
(EGFR). 
6.1. PEGylated and Biotinylated Lipid Particles 
Biotinylated liposomes stabilized with PEG were prepared using a detergent dialysis 
technique described for the preparation of SPLP (Wheeler et al., 1999). This method was 
adapted for the encapsulation of small QD655 (~10 nm) in a novel approach for delivering this 
fluorescent nanoparticles into cells.  
Three different BLP formulations were investigated for their receptor-mediated uptake, 
these including PEG-Ceramides (carbon chains lengths C20 and C8) and a pH sensitive lipid 
PEG-DSGS at percentages ranging from 1.4 to 10 mol% PEG. 
Two main lipid particles populations were recovered after detergent dialysis, consisting of 
empty BLP and particles loaded with DNA (BLP-DNA) or QDs (BLP-QDs). As determined by 
DLS, BLP-DNA particles were far more heterogeneous in size than BLP-QDs for the same BLP 
formulation. This heterogeneity was evidenced by the presence of sedimenting particles 
when the PEG-lipid content in the formulation decreased from 10 to 2.7 mol% or when 
Ceramide C20 was replaced by Ceramide C8. These findings were not surprising and 
indicated that the amount of PEG-lipid was insufficient to effect steric stabilization of DNA 
loaded particles. The observed aggregates were probably the result of strong electrostatic 
interactions between negatively charged DNA with the cationic lipid DOTAP present at 6 
mol% in all formulations, after the detergent monomers were removed from the initial DNA-
lipid-detergent mixture during the dialysis process (Zuidam and Barenholz, 1999). Furthermore, 
only BLP-DNA formulated with 10% PEG-Cer-C20 showed particles of discrete sizes after 
detergent dialysis (Figure 3.1 and Table 3.2). These findings are in line with the reported 
behavior of SPLP stabilized with 10% PEG-Cer-C20 (Wheeler et al., 1999; Zhang et al., 1999). 
Interestingly, although the variations in PEG content directly affected the particle size and 
homogeneity of plasmid DNA loaded BLP, no differences were observed regarding plasmid 
DNA encapsulation efficiency or protection (Table 3.2). 
On the other hand, BLP with encapsulated QDs showed discrete sizes (100-130 nm) even 
for the BLP formulations containing the lowest PEG-lipid content (1.4% mol% PEG-DSGS and 
PEG-Cer-C8)(Fig 3.4). This supports the idea that electrostatic interactions between DNA and 
DOTAP are stronger than between carboxyl groups in QDs and amino groups in DOTAP, 
driving the aggregation of the DNA loaded particles. 
Non-encapsulated DNA or QDs, as well as empty BLP likely present after dialysis, were 
removed by ultracentrifugation in a sucrose density gradient. This technique has proven 
suitable for purification of DNA loaded (Fig. 3.2) and QD loaded particles (Fig. 3.4). An 
additional advantage was that BLP-DNA particles smaller than 350 nm were clearly 
separated from aggregates also containig DNA and lipids (Table 3.2). For BLP-QDs, the 
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sucrose density gradient allowed the purification of QD-loaded particles from free QDs (Fig. 
3.4A).  
Sucrose fractions analyzed by TEM revealed an average of 2 to 5 QDs successfully 
encapsulated in BLP ranging from 100 to 130 nm in size (Fig. 3.4B). Particle dimensions 
estimated from TEM were in excellent agreement with the mean hydrodynamic diameter of 
~110 nm as determined by DLS for BLP-QDs (Fig. 3.4C). The encapsulation of QDs in stabilized 
lipid particles by the detergent dialysis method was presented as a novel approach, without 
deleterious effect in the fluorescence of QDs. Additionally, the spherical morphology of BLP 
shown by TEM was confirmed by Atomic Force Microscopy. 
6.2. Single step conjugation for targeting and labeling of BLP 
The characterized BLP were surface modified with preformed complexes of EGF-QDs to 
target the delivery system to cells overexpresssing the EGFR. As monocolor complexes of 
EGF-QD525-BLP would not be distinguishable from free EGF-QD525 upon incubation with cells, 
two-color tagging approaches were designed to clearly identify the EGFR targeted particles 
(Fig. 4.1 and 4.8).  
In the approach presented in Fig. 4.1, QDs play a dual rol acting as surface tag on the BLP 
carrier (QD525) and as encapsulated cargo (QD655). The rationale behind this two-color 
labeling strategy was that only QD525 and QD655 that are colocalized would indicate the 
intracellular distribution of the targeted BLP and the fate of loaded QDs. In a continuous 
monitoring of the delivery process by confocal microscopy, colocalization of both QDs can 
be interpreted as the persistence of the cargo in the delivery carrier, whereas a gradual loss 
of colocalization would indicate that QDs are being released. 
The first observation was, that targeted EGF-QD525-BLP-QD655 were internalized by the A431 
cells, whereas non-targeted BLP-QD655 were not even bound to the membrane, suggesting 
that uptake of the particles was mediated by the EGFR (Fig. 4.2).  
The labeled and targeted BLP were continuously monitored using confocal microscopy 
during cell binding and uptake for periods longer than 1h without significant photobleaching 
(Fig. 4.4), highlighting the convenience of QDs as labeling probes for long-term imaging of 
dynamic processes.  
Upon internalization of EGF-QD525-BLP-QD655, the variations in the relative levels of 
colocalized intensities found for both QDs (Fig. 4.3 D-E) could have been due to an uneven 
distribution in the number of encapsulated QD655 and EGF-QD525 associated with individual 
BLP. Additionally, QDs intensity variation could be the result of endosomes fusion bringing 
several BLP together (Gruenberg et al., 1989).  
The colocalization of both QDs allowed a clear distinction between the targeted and 
QD655 loaded BLP (yellow-orange pseudocolors) and the independently internalized green 
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EGF-QD525 complexes (Fig. 4.3), avoiding the tedious purification of targeted BLP from free 
EGF-QDs. 
When internalization was continuously monitored during 60 min, colocalized dots clustered 
around the perinuclear region of the cell (Fig. 4.4) indicating that they were sorted from early 
endosomes (Hopkins et al., 1990). This observation was supported by cell uptake experiments 
and colocalization analysis in the presence of labeled Transferrin used as an early-endosome 
marker (Hanover et al., 1984; Lamaze et al., 1993). After 30 min only partial colocalization was 
observed and after 2 h no colocalization at all was evident between EGF and Transferrin (Fig. 
4.5), indicating that EGF tagged BLP as well as EGF-QDs preformed complexes were likely 
sorted from early endosomes (Hanover et al., 1984). 
The specificity of EGF-QD525-BLP-QD655 for the EGF receptor was supported by a 
competitive binding assay performed in the presence of 66-fold molar excess of free ligand 
EGF. Under these conditions, binding of EGF-QD525-BLP-QD655 to A431 cells was completely 
abolished (Fig. 4.7A and B). In line with these observations, CHO cells and WM983A 
melanoma cells that do not express the EGFR showed no binding of the targeted particles 
(Fig. 4.7C and D). 
As mentioned above the observed colocalization of both QDs after 2 h was interpreted as 
the persistence of the cargo in the delivery carrier. Therefore, the delivery ability of targeted 
BLP was examined after 4 and 12 h. Formulations of BLP-QDs containing a pH sensitive PEG-
lipid were expected to promote BLP-endosome bilayers contact and destabilization by 
protonation during the acidification experienced in the endocytic process (Li et al., 2005), 
whereas PEG-ceramides with short acyl carbon chains (Shi et al., 2002) were expected to 
promote destabilization of BLP by lipid exchange. However, even for the lowest PEG content 
(1.4%) in BLP formulations, the presence of colocalizated QDs at 12 h after EGFR targeted 
delivery indicated that QDs remained encapsulated and presumably trapped in endo-
lysosomal compartments (Fig.4.6). This finding could be explained by the shielding effect of 
PEG, which does not hinder the accesibilitiy of EGF, but presumably prevents the contact 
between BLP-endosome bilayers required for cargo release. These results obtained with QDs 
loaded particles suggested that DNA release could also be hampered assuming that 
encapsulated DNA would follow a similar route as the encapsulated QDs with identical 
formulation and similar size. Therefore, the following aim was to study the behavior of 
targeted and labeled BLP with encapsulated DNA by colocalization analysis employing the 
two-color labeling approach presented in Fig. 4.8. In this case, both QDs were surface-
coupled to the BLP, while the encapsulated DNA was unlabeled. One of the QDs was 
carrying the ligand (EGF-QD525) whereas the second color QD655 remained untargeted. As 
free QDs do not internalize into cells in the absence of ligand, the rationale behind this 
strategy was that only QD655 particles bound to EGF-QD525-BLP-DNA would be endocytosed. 
Therefore, the intracellular fate of BLP-DNA was monitored by colocalization of both QDs and 
6. Discussion 
 89 
the ability to release the plasmid was examined quantifying the GFP expression from the 
reporter gene encapsulated in these targeted BLP.  A remarkable observation was that only 
10 min incubation with A431 cells was sufficient to promote receptor-mediated uptake of the 
targeted particles (Fig. 4.10) showing a similar time response as observed for BLP-QDs. After 
48 h treated cells showed improved GFP expression demonstrating that, although at a very 
low efficiency, endosomal escape of plasmid was indeed taking place. The presence of 
targeted BLP (colocalized QDs) in cells that do not express GFP suggested that the low 
transfection levels reflect more a difficulty to achieve endosomal escape rather than a 
hindered binding or internalization. Consequently, the two-color labeling strategy proposed 
for BLP-DNA particles provided information about the efficiency of the gene delivery system 
as well as the potential barriers that BLP may encounter during the uptake process. 
It was demonstrated by different approaches that the size of the carrier determines the 
internalization pathway as well as the processing of the gene carrier thus, directly affecting 
the transfection efficiency (Rejman et al., 2004). In this connection, it was of interest to 
compare the targeting effect between non-purified BLP after detergent dialysis, still 
containing aggregates (>1 µm), and purified particles of discrete sizes <350 nm recovered 
from sucrose density gradient. 
Due to the low levels of GFP expression obtained with the dual-labeled and targeted 
particles, a two-step targeting procedure was employed in order to decrease possible 
crosslinked aggregates between BLP and EGF-QDs and to improve the initial binding of BLP-
DNA to cell receptors. First, A431cells were incubated with preformed complexes of EGF-QDs 
and, in a second step, incubated with BLP containing the same total amount of plasmid 
DNA. In the case of non-purified fractions, the total amount of DNA added included a 40% of 
free non-encapsulated plasmid, DNA loaded BLP and DNA containing aggregates and for 
purified fractions the total DNA plasmid added was considered to be encapsulated.  
For non-purified fractions, a similar percentage of GFP expressing cells were determined 
for targeted and non-targeted delivery of BLP-DNA, evidencing that non-targeted particles 
were equally efficient to transfect cells as targeted particles. Since free plasmid added at 
equal amounts as the encapsulated DNA did not lead to GFP expression in cells, the 
transfection activity observed for non-purified fractions could have been generated by DNA-
loaded BLP and aggregates of lipid-DNA, the later probably entering through another non-
receptor mediated route. 
Not surprisingly, targeted BLP showed a 3-fold increase in GFP expression after purification 
as compared to the purified but non-targeted particles (Table 4.1), indicating that after 
removing aggregates the contribution to the transfection activity by unspecific uptake was 
minimized.  
The low (5%) overall efficiency of the targeted system was expected, considering that 
targeted BLP are formed by multivalent components. On one hand, the biotinylated 
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particles contain, at least, two available biotins as has been demonstrated by colocalized 
dots upon surface tagging BLP with QD525 and QD655 (Fig. 4.10). The second multivalent 
component is the streptavidin-coated QD, which acts as a bridge to couple BLP and EGF in 
a single particle. Although the stoichiometry of EGF:QD ratio has been carefully controlled in 
cell binding experiments previously described in our lab (Lidke et al., 2007), it was not evident 
that the addition of BLP, variable in size, to the remaining free streptavidins in EGF-QDs 
preformed complexes could have been equally controlled. Furthermore, due to this size 
variation within BLP, the number of biotin molecules per BLP could not be determined. 
Although increasing the number of EGF ligands per particle should in principle improve the 
binding to cells and increase the number of internalized particles, the larger size of the carrier 
would probably interfere with the receptor-mediated endocytosis. After ligand-induced 
receptor dimerization, autophosphorylation of the cytoplasmic domain of the tyrosine kinase 
receptor erbB1 (EGFR) is known to be essential for internalization through the rapid clathrin 
dependent route (Marmor et al., 2004). The EGF induced stimulation and activation of the 
signalling cascade by targeted BLP is part of the ongoing work, relevant since EGFR activity 
controls a wide variety of biological responses (Bublil and Yarden, 2007). 
6.3. Non-covalent Quantum Dot labeling of plasmid DNA 
Elucidating the intracellular transport mechanisms of delivered genes has been a 
challenging task because of the difficulties in labeling DNA without affecting its biological 
activity. Labeling strategies to attach QDs to plasmids while maintaining a functional DNA 
are still required. A more recently approach is to bind non-covalently any label or biological 
entitiy to DNA by employing molecular beacons such as bis-PNA (Svahn et al., 2004). PNA 
specifically hybridizes by strand invasion into a target sequence in supercoiled plasmid DNA 
providing a controlled and sequence specific tagging of DNA (Nielsen and Egholm, 1999).  
Therefore, as a final aim, the idea of obtaining a QD labeled DNA as a potential cargo for 
the targeted BLP was appealing, since a labeled plasmid would provide information about 
the physical barriers encountered by the encapsulated plasmid and the efficiency of 
nuclear translocation upon DNA release. 
In principle, a single QD per plasmid can provide enough signal for the detection at the 
single molecule level (Crut et al., 2005). This is relevant since a single QD can be 2 to 10 fold 
larger than conventional organic fluorophores (Michalet et al., 2005) and multiple QDs may 
affect the biological activity or nuclear translocation of the labeled plasmid. Consequently, 
the first task was to achieve the specific hybridization of a single biotin-bis-PNA entity 
synthetized to recognize a 12 bp target sequence in the plasmid pEGFP-C1. Once, the biotin-
bis-PNA sequence specificity was demonstrated by band shift assay in gel electrophoresis 
(Fig. 5.2), the biotinylated Hybrids were labeled with StAv-QDs. Scanning by AFM indeed 
confirmed the presence of a single QD attached to the biotin-bis-PNA binding site in the 
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plasmid (Fig. 5.5) and the labeled QD-Hybrids were clearly detected by fluorescence 
microscopy (Fig. 5.6). Although preliminary and still limited by the low yield of biotinylated 
Hybrids obtained, these QD-DNA particles appear as an attractive cargo for targeted BLP. 
6.4.  Rational liposome design 
The increasing requirements of lipid-based delivery systems to accomplish their 
therapeutic activity have propelled multiple designs in which liposomes are viewed as a 
‘ready to use’ toolbox able to open the route into the cells, increasing the efficacy while 
reducing the side effects (Torchilin, 2005; Dos Santos et al., 2007).  In the schema of Fig. 6.1 a 
new-generation liposome is presented that can be modified either on its surface or by 
loading molecular entities in order to modulate stability, specificity, labeling and function. 
Among the chemical modifications that account for this versatility are: 
a. surface coating with a protective polymer to favor long-term circulation and 
prevent  unspecific interactions before reaching the target tissue. 
b. inclusion of a positively charged lipid or polymer to condense and complex the 
loaded DNA. 
c. addition of stimuli-sensitive lipids to promote the endosomal escape. 
d. conjugation of a ligand to target a specific cell receptor. 
e. coating with cell penetrating peptides to favour membrane translocation.  
f. inclusion of a lipophilic drug to act as a therapeutic agent. 
 
According to the results obtained during this thesis, the contribution proposed to the 
rational design involves: 
g. labeling with two colors of QDs on the surface and in the internal space of the 
carrier for the real-time monitoring of cell binding, uptake and cargo release 
processes. 
h. incorporation of plasmid labeled with a single StAv-QD that can be further modified, 
for instance with a biotinylated nuclear localization signal to drive the plasmid 
vector into the nucleus. 
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Figure 6.1: Schematic representation of a new-generation of BLP. See text for details. Adapted from 
(Torchilin, 2005). 
 
In this thesis, I contributed by developing a multifunctional delivery system with sensitive 
detection. The addition of Quantum Dots into liposomal carriers with a dual rol, as cargo and 
as a surface tag will provide a flexible system for targeting and monitoring lipid-mediated 
delivery processes. The system will also contribute to a better understanding of the uptake 
mechanisms of liposomes by cells as well as the physical barriers to the effective gene or 
drug release and therapeutics.  
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The major outcome of this thesis was the design of a versatile lipid-based carrier, able to 
encapsulate small nanoparticles such as the fluorescent QDs for live-cell imaging and 
macromolecules with a potential therapeutic application such as plasmid DNA. 
The targeting strategies applied combine the flexibility of the biotin-streptavidin linkage for 
ligand coupling, the photostability and bright fluorescence of QDs and the pharmacokinetic 
and drug delivery capabilities of sterically stabilized liposomes. 
The optimization of the BLP formulation with other available pH-sensitive lipids and 
exchangeable lipids with high rate transfer to promote endosomal escape within minutes 
may certainly improve the gene delivery efficiency of the developed BLP system.  
The knowledge of the average number of biotins per BLP will allow controlling the 
stoichiometry of ligand-QD preformed complexes that can be added to rationally improve 
cell binding conditions, particularly necessary in the case of certain tumor cells with 
overexpressed receptors that are rapidly cleared from the cell surface by ligand-induced 
endocytosis. 
The bicolor QD labeling strategy for the BLP was designed for monitoring the specificity of 
BLP binding and uptake in live cells by fluorescence confocal microscopy. Despite the 
multivalency of the BLP and QDs, that prevents controlled stoichiometry of ligand-carrier,    
the overall specificity of the BLP system was not affected. The colocalization of green 
emitting QD525 and red emitting QD655, allowed the immediate recognition of the targeted 
particles from the untargeted counterparts, as well as the presence of free EGF-QD525 
complexes during live-cell imaging. A purification procedure, otherwise unavoidable in 
monocolor labeling, is by-passed.  
The targeted and labeled BLP can serve as gene or QD delivery platform for targeting 
different tumor cells, providing a long-term probe for imaging and diagnosis. Any 
biotinylated ligand can be in principle conjugated to streptavidin-coated QDs whenever the 
size of the final complex does not interfere with its receptor recognition, internalization and 
intracellular function. This approach can be used to elucidate the fate of lipid particles in real 
time, providing more refined information on the still poorly understood trafficking process and 
subcellular barriers encountered by lipid-based carriers. 
The non-covalent labeling of plasmid DNA using a single QD and a bis-PNA anchor 
directed to a specific target sequence is being conducted to further characterize the 
process involved in EGFR-targeted and non-targeted gene delivery. The preliminary results 
obtained open an interesting possibility for loading labeled DNA in BLP that can be tracked 
in real time to follow the route into the nucleus. 
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